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Abstract 
Inositol pyrophosphates (PP-InsPs) are a well conserved group of second 
messengers that are involved in a plethora of cellular processes including phosphate 
homeostasis, insulin signaling, and apoptosis. Despite much effort, it is still mostly 
unknown how PP-InsPs exert their diverse functions. In order to decipher the 
mechanisms, researchers have relied either on metabolic labeling with radioactive 
inositol or on electrophoretic separation on polyacrylamide gels but these methods 
either lack ease of use or sensitivity. Therefore, two new analytical tools, based on 
nuclear magnetic resonance (NMR) spectroscopy, and liquid chromatography 
coupled mass spectrometry (LCMS), were developed. 
To overcome the limited sensitivity provided by NMR spectroscopy, a high yielding 
synthesis of NMR-active 13C-labeled inositol was designed and optimized. 
Furthermore, a chemoenzymatic synthesis of all mammalian PP-InsPs isomers was 
developed that relied on a scalable purification strategy utilizing precipitation with 
Mg2+ ions. Human cells were metabolically labeled with 13C-inositol and the prepared 
PP-InsPs were used as standards to identify fingerprint peaks in the NMR-spectra of 
the labeled cells. These fingerprint signals enabled the quantification of the 
corresponding molecules. 
The LCMS-based method was envisioned to be based on the derivatization of the 
highly charged inositol pyrophosphates to their corresponding methyl esters by 
trimethylsilyldiazomethane. The uncharged, permethylated InsPs and PP-InsPs were 
suitable for LC separation and MS measurement, and provide a sensitivity 
unmatched by NMR spectroscopy. The method was established using inositol 
hexakisphosphate (InsP6), a simpler analog of PP-InsPs, and methylated InsP6 could 
be detected at quantities as low as 10 femtomole, emphasizing the validity of the 
approach. However, the adaptation of the derivatization for PP-InsPs proved 
challenging as the reaction caused degradation of the analyte but strategies to 
circumvent the decay by changing the derivatization agent to diazomethane were 
promising. 
In summary, both the NMR spectroscopy based method and the derivatization-LCMS 
approach, once fully developed, provide great versatility and will be indispensable for 
ix 
 
the research of inositol poly- and pyrophosphates. NMR spectroscopy will provide 
information on PP-InsPs in complex mixtures while the high sensitivity of mass 
spectrometry will enable the quantification of low-abundant PP-InsPs, thereby 
reciprocally complementing the other method. 
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Zusammenfassung 
Inositolpyrophosphate (PP-InsP) sind eine Gruppe sekundärer Signalmoleküle, die in 
einer Vielzahl zellulärer Prozesse, von Phosphathomeostase über 
Insulinsignalisierung bis Apoptose eine Rolle spielen. Trotz großem Aufwand ist die 
Art und Weise, wie PP-InsPs ihre Funktion ausführen, noch weitgehend unbekannt. 
Um den zugrundeliegenden Mechanismus zu entschlüsseln, nutzen Forscher bisher 
hauptsächlich Isotopenmarkierung mit radioaktivem Inositol oder elektrophoretische 
Auftrennungen auf Polyacrylamidgelen, doch diese Methoden sind entweder 
schwierig anzuwenden oder nicht sensitiv genug. Deshalb wurden zwei neue 
analytische Methoden basierend auf Kernspinresonanzspektroskopie und 
Flüssigchromatographie mit Massenspektrometrie-Kopplung (LCMS) entwickelt. 
Um die limitierende Sensitivität der Kernresonanzspektroskopie zu umgehen, wurde 
die Synthese von kernspinresonanzaktivem, 13C-markiertem Inositol optimiert. Des 
Weiteren wurde eine chemoenzymatische Synthese für alle Säugetier-PP-InsP-
Isomere entwickelt, die auf der skalierbaren Ausfällung mittels Mg2+ Ionen basiert. 
Menschliche Zellen wurden mit 13C-Inositol isotopenmarkiert und in den Spektren der 
Zellextrakte wurde, basierend auf den PP-InsP-Standards, Fingerabdrucksignale 
identifiziert mit denen die Konzentrationen der dazugehörigen Moleküle bestimmt 
werden konnte. 
Die LCMS basierte Methode wurde auf dem Prinzip der Umsetzung von 
hochgeladenen Inositolpyrophosphaten zu ihren korrespondieren Methylestern 
mittels Trimethylsilyldiazomethan geplant. Die ungeladenen, permethylierten PP-
InsPs wären geeignet für LC-Auftrennungen und MS-Messungen und sollten eine 
von Kernspinresonanzspektroskopie nicht erreichbare Sensitivität ermöglichen. Die 
Methode wurde mittels Inositolhexakisphosphat (InsP6), einem einfacheren PP-InsP-
Analog, etabliert und methyliertes InsP6 konnte in Mengen von 10 femtomol detektiert 
werden. Die Adaption der Methode für die PP-InsPs gestaltete sich jedoch 
herausfordernd, da der Analyt während der Reaktion zersetzt wurde. Ein Wechsel zu 
Diazomethan als Methylierungsagens zeigte vielversprechende Resultate. 
Zusammenfassend zeigten sowohl die kernspinresonanzspektroskopiebasierte 
Methode als auch die Herangehensweise mittels Derivatisierung gefolgt von LCMS, 
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sobald sie vollständig entwickelt sein wird, vielversprechende Ergebnisse und sie 
werden unverzichtbare Werkzeuge für die Erforschung von Inositolpyrophosphaten 
sein. 
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Chapter 1: Inositol pyrophosphates are important 
signaling moleculesa 
1.1 Inositol phosphates are cellular messengers 
Small molecule messengers are key components in cellular decision-making 
processes.1 Among those, inositol-based signaling molecules occupy a privileged 
node and include both water-soluble, diffusible inositol phosphates (InsPs), as well as 
the lipid-anchored phosphatidylinositol phosphates (PtdInsPs).2,3 The InsPs are 
derived from the head group of PtdIns(4,5)P2 that is cleaved from its diacyl glycerol 
lipid tail by phospholipase C (PLC) (Figure 1.1). The resulting Ins(1,4,5)P3 is a Ca
2+ 
releasing factor and an excellent example for a second messenger.4 Ins(1,4,5)P3 is 
subsequently phosphorylated via various inositol tetrakisphosphate (InsP4) isoforms 
to yield Ins(1,3,4,5,6)P5 (InsP5). The responsible kinases are inositol polyphosphate 
multikinase (IPMK) and inositol tetrakisphosphate 1-kinase (ITPK1). InsP5 is then 
phosphorylated by inositol pentakisphosphate 2-kinase (IPK1) to provide the fully 
phosphorylated inositol hexakisphosphate (InsP6) (Figure 1.1).  
Remarkably, eukaryotic cells comprise a subgroup of inositol polyphosphates 
termed inositol pyrophosphates (PP-InsPs) which contain, in addition to the six 
phosphate esters present in InsP6, up to two additional phosphoryl groups in the form 
of di- or pyrophosphates. These high energy bonds are formed by two families of 
conserved kinases, the inositol hexakisphosphate kinases (IP6Ks) and 
diphosphoinositol pentakisphosphate kinases (PPIP5Ks). Removal of the 
pyrophosphate groups is catalyzed by diphosphoinositol polyphosphate 
phosphohydrolase 1 (DIPP1). In yeast, another pyrophosphatase is known, called 
Siw14.5,6 In all, the involved enzymes form a complicated network that is still not fully 
annotated e.g. no Siw14 homolog is known yet in mammals. This is noteworthy as 
the majority of the enzymes are conserved in all eukaryotes.  
  
                                                             
a
 Part of this chapter was taken from “Puschmann, R.
‡
; Harmel, R. K.
‡
; Nguyen Trung, M.; Saiardi, A.; 
Schmieder, P.; Fiedler, D. Harnessing 
13
C-Labeled Myo-Inositol to Interrogate Inositol Phosphate 
Messengers by NMR. Chem. Sci. 2019, 10 (20), 5267–5274.” (
‡
 contributed equally) 
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Figure 1.1. Biosynthetic pathway of inositol pyrophosphates. PLC: phospholipase C, IPMK: inositol 
phosphate multikinase, INPP5: Inositol Polyphosphate-5-Phosphatase, ITPK1: inositol 
tetrakisphosphate 1-kinase, IPK1: inositol pentakisphosphate 2-kinase, IP6K: inositol 
hexakisphosphate kinase, PPIP5K: diphosphoinositol pentakisphosphate kinase, DIPP1: 
diphosphoinositol polyphosphate phosphohydrolase 1. 
 
 
1.2 Functions of inositol poly- and pyrophosphates 
InsP3 is a well-known second messenger involved in Ca
2+ release and insulin 
signaling and has been extensively reviewed.4,7 IPMK then attaches phosphoryl 
groups to InsP3 and forms different InsP4 isomers that have a wide variety of 
activities, ranging from protein membrane recruitment, and regulation of protein-
protein interactions (Ins(1,3,4,5)P4) over Ca
2+ mobilization (Ins(1,3,4,5)P4), and the 
regulation of ClC-3 chloride channels (Ins(3,4,5,6)P4) to the maturation of B and T 
cells (Ins(1,3,4,5)P4).
8–15 Of special interest is the modulation of histone deacetylases 
(HDAC), here InsP4 binds to a pocket formed by HDAC and a corepressor protein, 
leading to activation of the enzyme. The resulting upregulation of deacetylation leads 
to a downregulation of transcription.16  
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IPMK attaches another phosphoryl group to InsP4 to generate InsP5, a compound 
that is involved PI3K/Akt activity regulation, angiogenesis and knockouts of its 
biosynthetic enzyme IPMK are embryonically lethal.17–19 The question remains if the 
lethality arises due to a lack of InsP4 and InsP5, the direct products of IPMK or 
whether the deprivation of all downstream metabolites is the main cause. 
Inositol hexakisphosphate possesses function in the context of mRNA export and 
necroptosis.20–23 A unanticipated role of InsP6 is as an integral structural component 
of several large protein complexes, including TIR1, the receptor of the plant hormone 
auxin, and in the maturation and release of HIV capsids.24–26 This role is reminiscent 
of the InsP4-HDAC complex and might point towards a general function of InsPs in 
the mediation of protein-protein complexes. 
PP-InsPs are involved in a wide variety of cellular processes and seem to connect 
different aspects of cellular homeostasis, like hormone signaling and nutrient 
homeostasis that are not usually thought of as directly linked (Table 1.1). Most of 
these phenotypes were discovered by knocking out one or more of the IP6Ks and 
PPIP5Ks responsible for PP-InsP synthesis. This approach led to a good 
understanding of the processes PP-InsPs are involved in but the mechanistic targets 
remain mostly elusive.  
5-Diphosphoinositol pentakisphosphate (5PP-InsP5) possesses a pyrophosphoryl 
group in the 5-position and is the best studied inositol pyrophosphate. 5PP-InsP5 is 
the major component of the cellular InsP7 pool. It is involved in a wide variety of 
cellular processes, some of which seem to rely only on 5PP-InsP5 and are 
independent of the IP6K isoform that synthesized the PP-InsP (i.e. phosphate 
homeostasis). However, some effects are dependent on the specific IP6K isoform 
(e.g. insulin sensitivity for IP6K1 or lifespan regulation in mice for IP6K3) 
(Table 1.1).27–30 This connection could be important in the context of specific 
inhibitors to treat, for example, diabetes, while having as little off-target effects as 
possible.  
1PP-InsP5 and InsP8 are synthesized by PPIP5Ks and not much is known about 
their cellular functions of 1PP-InsP5 (Table 1.1). An exciting exception is a link 
between InsP8 and phosphate sensing in mammals. Shears an coworkers found that 
free phosphate upregulates the kinase domain and downregulates the phosphatase 
domain of PPIP5K2, greatly increasing the rate of InsP8 production.
31  
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Table 1.1. Cellular processes associated with IP6Ks and PPIP5Ks. 
Enzyme Organism Effect Reference 
IP6K1 Mouse Regulation of exocytosis 32–34 
 Mouse Chromatin remodeling 35,36 
 Mouse DNA damage and repair 37,38 
 Mouse Hemostasis 39 
 Mouse Impaired spermatogenesis 30,40,41 
 Mouse, human Reduced migration and invasion 42,43 
 Mouse Neutrophil regulation 44–47 
 Mouse Insulin signaling and sensitivity 30,48–50 
 Human Phosphate homeostasis 27 
IP6K2 Mouse, human Promoting apoptosis 51–59 
 Mouse Cancer metastasis and cell migration 43,60 
 Human Phosphate homeostasis 27 
IP6K3 Mouse Morphology defects in synapse formation 61 
 Human Susceptibility to Alzheimer’s disease 62 
 Mouse Lifespan 29 
 Human Phosphate homeostasis 28 
Kcs1 Yeast Regulation of rRNA transcription 63 
 Yeast Regulation of inositol biosynthesis 64 
 Yeast Cell cycle progression 65 
 Yeast Phosphate homeostasis 66 
 Yeast Telomere maintenance 67,68 
PPIP5K1 Human Bioenergetics homeostasis 69 
 Human Downregulation of apoptosis 70 
 Human Cell migration 71 
 Human Hyperosmotic stress 72 ‬
PPIP5K2 human Phosphate homeostasis 31 
 Mouse, human Hearing loss 73 
 Human Survival in colorectal cancer 74 
 Human Type-I interferon response 75 
Vip1 Yeast Regulation of dimorphic shift 76,77 
 
 
1.3 Inositol pyrophosphates act via two distinct mechanisms 
Inositol pyrophosphates are thought to act via two distinct mechanisms 
(Figure 1.2). First, the binding of PP-InsPs to a protein to trigger an effect. This type 
of interaction requires PP-InsP binding domains that can interact with different forms 
of PP-InsPs. To date, the only known PP-InsP-specific binding domain is the SPX 
domain (named after SYG1/Pho81/XPR1 proteins).27,78–80 These domains are usually 
found on the N-terminus of proteins involved in phosphate metabolism.81–83 Recently, 
it was shown that SPX domains specifically interact with PP-InsP via a positively 
charged surface binding site.80 While plants and yeast contain several SPX-
containing proteins, mammals only possess one, XPR1 (Xenotropic and Polytropic 
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Retrovirus Receptor 1), which is a phosphate exporter, expressed predominantly in 
kidneys. It is therefore impossible to account for all characterized effects of PP-InsPs 
with just this one protein-PP-InsP interaction. Therefore, additional protein binding 
partners or domains other than SPX must exist. 
Apart from proteins that specifically interact with PP-InsPs as their endogenous 
ligand, it was shown that inositol poly- and pyrophosphates can bind to PH-domains 
and compete with their canonical PtdInsPs ligands. PtdInsP - PH-domain interactions 
localize the protein to the plasma membrane, an important regulatory element e.g., in 
Akt signaling. Increased levels of PP-InsPs have been shown to sequester Akt from 
the membrane, downregulating its activity.49,84 Another example is the 
downregulation of synaptotagmin dependent exocytosis by interaction of 5PP-InsP5 
with synaptotagmin’s C2B domain.85,86 In conclusion, two varieties of PP-InsP protein 
binding are proposed: interaction with PP-Ins-specific domains like SPX, and 
competitive binding to domains with distinct selectivity. 
The second mechanism of action of PP-InsPs was proposed soon after their initial 
identification. The high energy phosphoanhydride was suggested to participate in 
phosphoryl transfer chemistry. Indeed, Snyder and coworkers demonstrated that the 
radioactively labeled beta-phosphate of 5PP-InsP5 could be transferred to various 
proteins in a cell lysate.87 Unexpectedly, this process required only Mg2+ as a 
cofactor and no enzyme was involved. Subsequent work showed that the beta-
phosphate was transferred onto a pre-phosphorylated sidechain of the substrate 
protein.88 Hence, this non-enzymatic post translational modification (PTM) was 
termed protein pyrophosphorylation. In vitro, several targets of pyrophosphorylation 
have been described but an in vivo verification of this modification remains a much 
sought after question in the field.63,87 However, should this PTM be confirmed in vivo,  
      
Figure 1.2. PP-InsPs act via two distinct modes of action. 
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it would supplement the model of how PP-InsPs exert their diverse functions with 
additional information and could better explain the multifaceted phenotypes of PP-
InsPs. 
 
 
1.4 Methods for the detection of inositol pyrophosphates 
In order to dissect the molecular mechanisms that guide the diverse cellular 
effects of PP-InsP, it is essential to reliably and sensitively quantify PP-InsPs. 
Depending on the context this can mean quantifying either cellular PP-InsP pools or 
reaction products in biochemical reaction. This analysis, however, has proven to be 
the major bottleneck for the advancement of the field. Although the structure of InsPs 
appears simple, the detection of these compounds poses a challenge due to their 
lack of an analytical handle, high charge density, and propensity to precipitate with 
divalent metal cations.89,90 For the analysis of cellular inositol pyrophosphates, 
researchers traditionally have relied heavily on a radiolabeling approach where cells 
are supplied with tritiated myo-inositol (Figure 1.3a).91 The growing cells incorporate 
the [3H]myo-inositol into their PtdInsPs and, eventually, the pool of soluble PP-InsPs 
is labeled as well. While this method has enabled many seminal finding in the field, it 
is limited by several factors. [3H]myo-Inositol is only incorporated by growing cells 
and at least six doublings are required to achieve steady state labeling. The labeling 
can take from one night in the case of yeast up to several days for mammalian cells, 
that is, if the mammalian cells survive the constant exposure to ionizing radiation. A 
further limitation is the dependence on dedicated HPLC equipment for radioactive 
compounds, limiting this method to a few research groups worldwide. A parallel 
approach circumvented the use of radioactivity by analyzing HPLC fractions in the 
presence of a metal-dependent dye, but has remained sparsely used (Figure 1.3b).92 
More recently, a method based on gel electrophoresis was reported.93 Here, the 
extracted InsPs and PP-InsPs have to be enriched over TiO2 beads, and are then 
resolved on a high-percentage polyacrylamide gel (PAGE) (Figure 1.3c).94 Although 
the independence from radioactive tracers has allowed more laboratories to employ 
this approach, the lack of an InsP-specific analytical handle requires a more 
elaborate sample preparation and is limited to the detection of only the most highly 
phosphorylated InsPs (InsP6 and higher for cell extracts).  
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Liquid chromatography coupled mass spectrometry (LCMS), as an application for 
the analysis of small analyte amounts, is well established. This method has been 
mostly used for the analysis of inositol hexakisphosphate in food samples but was 
recently adapted for cellular PP-InsP pools (Figure 1.3d).95–98 All reported LCMS 
methods for the analysis of InsPs and PP-InsPs rely on ion exchange liquid  
 
Figure 1.3. Established methods for the analysis of inositol pyrophosphates. (a) Cells are grown with 
[
3
H]myo-inositol and labeled PP-InsPs are extracted. The PP-InsPs are resolved via SAX-HPLC and 
the radioactivity in each sample is detected via scintillation counting. (b) Unlabeled cells are extracted 
and the PP-InsPs are resolved on a SAX-HPLC and the PP-InsPs are detected via a metal dependent 
dye. (c) PP-InsPs are extracted from cells and enriched on TiO2 beads before resolution via PAGE 
and staining. (d) PP-InsPs are resolved on a SAX-HPLC and directly injected into mass spectrometer. 
The analytes are ionizes in negative ion mode. 
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chromatography, introducing large amounts of salt into the instrument (up to 570 mM) 
and use negative ionization mode. The highly charged InsPs are difficult to ionize 
and the methods have a limit of detection of > 1 pmol, rendering the method more 
sensitive than PAGE analysis but less sensitive than radiolabeling. Taken together, 
LCMS has not reached its potential yet and therefore seen no adoption in the field as 
of now. 
Similar to the analysis of cellular PP-InsPs, the quantification of inositol 
pyrophosphates in biochemical reactions has relied on the same basic methods and 
only the differences are discussed here. 
In addition to the use of [3H]myo-inositol hexakisphosphate as a radioactive tracer, 
[32P] was used in the form of ATPγ32P to monitor kinase reactions as well.99,100 When 
analyzing in vitro reactions by PAGE, a TiO2 enrichment is usually not required as the 
samples contain less contaminants then cell extracts.101 
The methods mentioned above have been used to varying degrees, but cannot 
provide structural information about the InsPs and PP-InsPs, such as the clear 
distinction of the structural isomers of PP-InsPs. Furthermore, radiotracers are so far 
the only valid approach to quantify low-abundant PP-InsPs. The methods also lack 
the ability to monitor conversion of InsP species in real time in vitro, thereby forfeiting 
informative kinetic insight contained within biochemical experiments. In addition, 
because of the various separation and resolution steps, direct measurements in 
complex samples, such as cell extracts, have not been possible so far. These 
drawbacks have limited the advancement of the field and new analytical tools are 
urgently needed. 
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1.5 Goal 
The aim of this thesis is the development of analytical tools based on NMR 
spectroscopy and mass spectrometry to measure and quantify inositol poly- and 
pyrophosphates both in vitro and ex vivo. These methods are necessary to better 
correlate cellular concentrations with phenotypes to ultimately facilitate a better 
understanding of InsP and PP-InsP functions.  
NMR spectroscopy provides not only quantification of analytes, but also 
information on structure and conformation, enabling the differentiation of inositol 
pyrophosphate isomers, a feature no current analytical method is able to deliver. To 
take full advantage of NMR, however, 13C-labeled compounds are necessary. 
Therefore, scalable, high-yielding synthetic approaches for 13C-labeled myo-inositol 
and PP-InsPs have to be developed. 
The most significant limitation of NMR spectroscopy is its low sensitivity, restricting 
the applicability to medium analyte concentrations. For this reason, mass 
spectrometry’s superb sensitivity complements the analytical tool box well in that 
regard. To unlock the full potential of LCMS for the analysis of inositol poly- and 
pyrophosphates, the charge of the compounds has to be mitigated via a 
derivatization approach to allow for reverse phase separation and to facilitate analyte 
ionization. 
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Chapter 2: Synthesis of [13C6]myo-inositol and 
[13C6]inositol pyrophosphates
b 
2.1 Introduction 
Nuclear magnetic resonance (NMR) spectroscopy is a widely used method for 
the analysis of diverse substances. In the context of metabolomics, NMR 
spectroscopy is a powerful tool that can provide valuable information on the status 
of a cell.1–3 However, NMR suffers from its inherently low sensitivity, especially for 
nuclei other than 1H and 19F. The sensitivity and hence the applicability of carbon-
NMR measurements are greatly limited by two factors: the low gyromagnetic 
constant of 13C (γC = 67.2828 rad s
-1 T-1) and the low natural abundance of 13C of 
only 1.1 %.4 The low sensitivity can be partially overcome by the use of adequate 
pulse sequences that exploit the higher gyromagnetic constant of 1H (γH = 
267.5222 rad s-1 T-1) by transferring the magnetization to 1H before detection.5 The 
low abundance can be improved by using isotopically enriched compounds that 
contain > 99 % 13C. The selective labeling of compounds of interest also exploits 
the low background signal intensity in 13C 1D or 2D experiments and greatly 
enhances the achievable signal-to-noise ratio, rendering such experiments highly 
informative, especially in complex mixtures. 
For the study of PP-InsPs, scientists have relied on radioactive labeling of myo-
inositol or the corresponding inositol phosphates for cellular and biochemical 
assays, respectively.6 The drawbacks and limitations of this technique are 
discussed in depth in chapter three. By using a benign label in the form of 13C 
nuclei, NMR spectroscopy not only overcomes these limitations, it also offers an 
additional layer of information in the form of structural data, such as the distinction 
of PP-InsP isomers.  
For the application of 13C-labeled myo-inositol in metabolic labeling experiments 
and biochemical characterization of enzymes, large quantities of pure compound 
                                                             
b
 The results of this chapter were partially published in “Puschmann, R. 
‡
; Harmel, R. K. 
‡
; Nguyen 
Trung, M.; Saiardi, A.; Schmieder, P.; Fiedler, D. Harnessing 
13
C-Labeled Myo-Inositol to 
Interrogate Inositol Phosphate Messengers by NMR. Chem. Sci. 2019, 10 (20), 5267–5274.” and 
“Puschmann R.
‡
, Harmel R.K.
‡
, Dorothea Fiedler. ‘Scalable Chemoenzymatic Synthesis of Inositol 
Pyrophosphates’ Biochemistry. 2019, submitted” (
‡
 authors contributed equally). To provide a 
cohesive account, results obtained by RKH are included in this chapter and highlighted as such. 
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are essential. To date, synthetic approaches have relied either on expensive 
starting material in the form of [13C6]glucose-6-phosphate (7000 € per g
c) or were 
low yielding (9.9 % and 6.7 %).7–9 In addition, all methods lacked scalable 
purification strategies, reducing their practical use. In order to make 13C-labeled 
myo-inositol readily accessible and a viable tool, it is necessary to devise an 
efficient, scalable synthesis for it. 
While genetic studies have unraveled a plethora of biological processes 
regulated by PP-InsPs (Table 1.1), the mechanism of action remains unknown in 
most cases. Whenever a biochemical mechanism was provided, the researchers 
relied heavily on synthetic PP-InsP standards. Although the synthetic strategy for 
the preparation of PP-InsPs, especially 5PP-InsP5, has been vastly improved over 
the past years, the synthesis is still time consuming and low yielding (30 % starting 
from myo-inositol).10–12 In order to advance the study of PP-InsPs, it is essential to 
gain access to an easy, high-yielding, scalable, and time efficient synthetic route.  
In the past, enzymatic approaches were applied whenever the preparation of 
radioactive PP-InsPs was required. The synthesis was high-yielding and time 
efficient, however, this approach is limited to a few micrograms of product due to 
the employed purification strategy via SAX-HPLC.13,14 
In order to render the enzymatic synthesis of 5PP-InsP5, and PP-InsPs in 
general, more viable, a new purification strategy has to be developed and a robust 
expression system for a highly active IP6K and PPIP5K has to be established. 
This chapter describes a scalable, enzymatic synthesis of 13C-labeled myo-
inositol starting from 13C-labeled glucose. The [13C6]myo-inositol was used to 
optimize the chemoenzymatic synthesis of all mammalian PP-InsPs. By taking 
advantage of the high propensity of PP-InsPs to precipitate with Mg2+ ions, a 
scalable purification strategy for all mammalian PP-InsPs could be realized. The 
new synthetic route coupled with the precipitation procedure will provide large 
amounts of pure PP-InsP for the research community. 
  
                                                             
c
 The price at Eurisotop as of 2018. 
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2.2 Synthesis of 13C-labeled myo-inositol 
In order to analyze inositol-derived signaling molecules by NMR, my goal was to 
prepare large amounts of [13C6]myo-inositol (1). The synthetic strategy built upon 
the enzymatic route published by Saiardi and coworkers and was adapted to a 
scalable procedure by starting from inexpensive [13C6]glucose (2) (Figure 2.1).
7 To 
further simplify the synthesis, commercially available hexokinase was used in the 
first step for the conversion of 2 to [13C6]glucose-6-phosphate (3).
15 The key step, 
the isomerization of 3 to [13C6]myo-inositol-3-phosphate (4) is centered around 
inositol phosphate synthase (IPS) from Archaeoglobus fulgidus. The enzyme’s 
origin from a hyperthermophilic organism renders the purification of this enzyme 
exceedingly simple (after boiling of the lysate only IPS remains in the 
supernatant), adding to the ease of adaptability of the synthesis for other research 
groups.16 The isomerization procedure of Saiardi and colleagues was modified to 
work with Mg2+ instead of paramagnetic Mn2+ to enable reaction progress 
monitoring by NMR (Figure 2.2). The monitoring ensured full conversion during 
this key step and enabled the usage of commercially available bovine alkaline 
phosphatase (AP) instead of the self-made and inositol-3-phosphate specific 
inositol monophosphatase for the dephosphorylation of 4 to 1.  
The resulting [13C6]myo-inositol contained significant amounts of buffer 
components and salts, hence it was not pure enough to carry it over into the next 
 
Figure 2.1. Enzymatic synthesis of [
13
C6]myo-inositol. (a) Improved synthetic route starting from 
[
13
C6]glucose. (b) Original synthetic route as published by Saiardi and coworkers.  IPS: 
Archeoglobus fulgidus inositol phosphate synthase (expressed), IMPA: human inositol 
monophosphatase (expressed), Hxk: Saccharomyces cerevisiae hexokinase (commercial), AP: 
bovine alkaline phosphatase (commercial). 
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Figure 2.2. Conversion of (a) [
13
C6]glucose-6-phosphate to (b) [
13
C6]myo-inositol-3-phosphate. The 
reaction progress can be monitored via the peaks of the anomeric C1 atom at 92 and 96 ppm, 
respectively. 
 
reactions towards the various InsPs. Because purification attempts via ion 
exchange, normal-phase, and reverse-phase chromatography proved difficultd, a 
chemical derivatization strategy was employed. The crude mixture from the 
dephosphorylation reaction was acetylated using acetic anhydride in pyridine. The 
resulting [13C6]myo-inositol hexakisacetate (S1) could then be purified by silica 
chromatography. After basic deprotection and subsequent precipitation 1 was 
obtained in high purity and 50 % overall yield.  
This method can be extended for other 13C labeling patterns of glucose as well, 
and [4-13C]- and [4,5-13C2]myo-inositol have been prepared from [1-
13C]glucose 
and [1,2-13C2]glucose respectively. 
  
                                                             
d
 These tests were conducted by RKH. 
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2.3 Synthesis of [13C6]InsP5 and [
13C6]InsP6 
With pure 1 in hand, the syntheses of [13C6]InsP5
e (5) and [13C6]InsP6 (6), the 
most abundant soluble InsPs were conducted.17,18 Standard literature procedures 
for the unlabeled compounds were used and both compounds were obtained in 
good yield (Figure 2.3a). The 1H,13C-HMQC spectra for both compounds 5 and 6 
displayed four signals each, due to their plane of symmetry. Notably, the spectra in 
Figures 2.3b and 2.3c were recorded at an InsP concentration of 5 µM with 32 
scans, highlighting the remarkable sensitivity provided by 13C-labeling. This feature 
encouraged us to continue with the development of a NMR based method for the 
analysis of InsPs and PP-InsPs.  
 
Figure 2.3. Synthesis and characterization of [
13
C6]inositol polyphosphates. (a) reagents and 
conditions: (i) CSA, trimethyl orthobenzoate, TEA in DMSO at 80 °C; 85 % yield (ii) TFA in H2O at 
rt; quantitative yield (iii) 5-phenyltetrazole, xylyl phorsphoramidite, mCPBA in DCM at rt; 79 % yield 
(iv) Pd(OH)2/C in MeOH/H2O at rt; 88 % yield (v) NH3 (aq.) at 60 °C; 65 % yield (vi) Xylyl 
phosphoramidite, 1H-tetrazole, mCPBA in DCM at rt; 38 % yield (vii) Pd(OH)2/C in MeOH/H2O at rt; 
83 % yield (b) 
1
H,
13
C-HMQC spectrum of [
13
C6]InsP5 at 5 µM. (c) 
1
H,
13
C-HMQC spectrum of 
[
13
C6]InsP6 at 5 µM. The positions of the carbon atoms and the solvent signal are indicated. 
 
  
                                                             
e
 [
13
C6]InsP5 was synthesized by RKH. 
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2.4 Synthesis of [13C6]PP-InsPs 
For the best characterized PP-InsP, [13C6]5PP-InsP5 (7), the chemical synthesis, 
despite recent advances, still requires several steps and promises yields of only 
20-25 % starting from myo-inositol.19,20 While this low yield is acceptable for 
unlabeled substance, the precious nature of the labeled starting material rendered 
this approach unusable. As an alternative, we envisioned – similar to [13C6]myo-
inositol – an enzymatic route for a simple and scalable one-step preparation of 
[13C6]5PP-InsP5 from 6.  
To this end, ehIP6KA was utilized as it is the IP6K with the highest known 
activity.21 Stephen Shears (National Institute of Environmental Health Sciences, 
National Institutes of Health, USA) kindly provided us with the required expression 
plasmid, which contained IP6Ka in a pDest-556 vector (with a His-MBP-tag). The 
IP6KA open reading frame (ORF) was sub-cloned into a pET15b vector (with a 
His-tag), yielding good expression results. By employing an ATP-regenerative 
system based on creatine phosphate and creatine kinase, the reaction equilibrium 
was shifted towards 5PP-InsP5. Further optimization of the conditions using NMR 
lead to full conversion within 45 minutes.  
The isolation of enzymatically produced PP-InsPs previously relied either on 
SAX-HPLC purification or separation via preparative PAGE.13,14 Both methods, 
while providing the desired material, lack scalability and contaminate the product 
with large amounts of salt. To overcome this limitation, I took advantage of the 
propensity of PP-InsPs to form insoluble salts with Mg2+ ions under alkaline  
 
Figure 2.4. Synthesis and characterization of [
13
C6]5PP-InsP5. (a) Reagents and conditions: MES 
pH 6.4, NaCl, ATP, creatine phosphate, MgCl2, DTT, IP6KA in H2O at 37 °C; quantitative yield. (b) 
1
H,
13
C-HMQC spectrum of [
13
C6]5PP-InsP5 at 5 µM. The positions of the carbon atoms and the 
solvent signal are indicated. 
 23 
 
conditions.22,23 Indeed, the addition of MgCl2 to the reaction mixture resulted in the 
selective precipitation of all InsPs, while all other reaction components remained in 
solution, including ATP and creatine phosphate. The 5PP-InsP5–Mg salt was 
collected, washed and resolubilized by treatment with metal ion chelating resin, 
affording 5PP-InsP5 in excellent yield (quantitatively on a 50 mg scale and 79 % 
on a 350 mg scale) and high purity as the ammonium salt (Figure 2.4). 
The underlying ideas of the synthesis and purification for 7 can also be applied 
to make [13C6]1,5(PP)2-InsP4 (8) and [
13C6]1PP-InsP5 (9). Human 
diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) phosphorylates 7 to 8 
and 6 to 9, respectively (Figure 1.1). However, compared to IP6KA, PPIP5K2 is a 
less efficient enzyme and to obtain the large amounts of PPIP5K2 required, a 
codon optimized ORF was ordered and sub-cloned into a pSUMO plasmid to 
generate a His6-sumo-PPIP5K2 fusion protein. Sumo-PPIP5K2 displayed 
adequate activity despite the tethered sumo protein and was therefore used as 
such without cleavage of the tag. The catalytic activity of PPIP5K2 varies for both 
its substrates, with 5PP-InsP5 being the better substrate compared to InsP6.
24 
Therefore, the enzyme concentration in the reaction was raised and the reaction 
time prolonged to 5.5 hours (to make 8) and 18 hours (to make 9), respectively 
(Figure 2.5). After precipitation, 8 was obtained in excellent purity and good yield  
 
Figure 2.5. Synthesis of (a) [
13
C6]1,5(PP)2-InsP4 and (b) [
13
C6]1PP-InsP5. The respective 
31
P 
spectrum is displayed on the right. Reagents and conditions: MES pH 6.4, NaCl, ATP, creatine 
phosphate, MgCl2, DTT, PPIP5K2 in H2O at 37 °C. 
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(77 % on a 130 mg scale). [13C6]1PP-InsP5, however, was contaminated with 
byproducts, probably a consequence of the long reaction time (18 hours). 
Therefore, the product was separated from the mixture by means of SAX-FPLC 
(Fast Protein Liquid Chromatography) with a NH4HCO3 gradient and after 
lyophilization pure 9 was obtained in good yield (68 %).f 
 
 
2.5 Synthesis of 5PP-InsP5-β
32P 
Radioactive tracers have played a pivotal role in the field of inositol 
pyrophosphates, both in the form of tritiated myo-inositol and 32P-labeled 5PP-
InsP5. The latter being the only option for identification of protein 
pyrophosphorylation targets in vitro.  
To ensure the highest labeling efficiencies, the published protocol used an 
excess of InsP6 over ATP to force the incorporation of 
32P from ATPγ32P into 5PP-
InsP5. The method required a subsequent purification by SAX-HPLC to separate 
the unreacted InsP6 and residual ATPγ
32P from the product, as those 
contaminants could potentially interfere with subsequent assays. The limited scale 
is not an issue in this context, however, the high amount of salt contaminations, 
and especially the requirement of a dedicated radioactive HPLC instrument restrict 
this tool to a few select groups. In order to facilitate access to 32P-labeled 
compounds, I envisioned a modified procedure for the preparation of 32P 
containing PP-InsPs based on the precipitation protocol established for the 
[13C6]5PP-InsP5 (Figure 2.6a). 
Separating the 5PP-InsP5-β
32P (10) from the reaction mixture via precipitation 
would render the limiting SAX-HPLC separation obsolete. To ensure proper 
precipitation the reaction volume had to be increased 10-fold compared to the 
established 32P-labeling approach. Furthermore, to guarantee full conversion and 
hence limit inseparable InsP6 contamination to a minimum, the ATP concentration 
had to be increased, while also incorporating a creatine kinase-based ATP-
regenerating system. With minor adjustments to the reaction time and MgCl2 
content, the reaction proceeded to full conversion, as tested with nonradioactive 
compound. 
                                                             
f
 The synthesis and purification was performed by RKH. 
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After the initial precipitation/chelation, the purified 5PP-InsP5-β
32P solution was 
subjected to SAX-HPLC separation and scintillation counting for testing its purity 
(Figure 2.6b). Unexpectedly, the putative product contained significant amounts of 
ATPγ32P and over-phosphorylated InsP8 species. The InsP8 species was not a 
major concern, however, the residual ATPγ32P could lead to a false positive signal 
if a kinase would transfer the γ32P-phosphate to a protein. To tackle this issue, I 
tested apyrase treatments at two different points in the protocol to degrade 
ATPγ32P. When apyrase was added before the initial precipitation, a significant 
amount of the liberated phosphate, including the 32P-phosphate, was co-
precipitated, resulting in a large amount of radioactive contaminants and low yield. 
However, if the apyrase treatment was applied after the precipitation, only the 
carried-over ATPγ32P was further degraded, enabling the isolation of highly pure 
5PP-InsP5-β
32P after a second precipitation step (Figure 2.6b). 
The major drawback of this procedure is the relatively low specific activity (ca. 
50-fold lower) of the generated radiolabeled 5PP-InsP5 as compared to the 
traditional method. To test if the activity was high enough to observe protein 
pyrophosphorylation, a fragment of yeast NSR1, an established  
 
Figure 2.6. Synthesis of 5PP-InsP5-β
32
P. (a) Reagents and conditions: (i) MES pH 6.4, NaCl, ATP, 
creatine phosphate, MgCl2, DTT, IP6KA in H2O at 37 °C. (b) Chromatogram
 
of of 5PP-InsP5-β
32
P 
after different purification methods. (c) Final procedure for the preparation of 5PP-InsP5-β
32
P. (d) 
Protein pyrophosphorylation of phospho-NSR1 to test purity of the prepared 5PP-InsP5-β
32
P.  
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pyrophosphorylation target, was incubated with the prepared radioactive 5PP-
InsP5-β
32P (Figure 2.6d). Pre-phosphorylated NSR1 (pNSR1) was modified by 10  
as expected, while non-phosphorylated NSR1 was not. More importantly, a control 
of NSR1 and casein kinase 2 showed no signal, highlighting that the apyrase 
treatment removed all detectable ATPγ32P from the reaction product (Figure 2.6d).  
The benefit of this route is the easy accessibility to radiolabeled compounds for 
groups without specialized equipment and although the specific activity of the 
product is reduced compared to the literature method, the achievable signal is 
strong enough to detect protein pyrophosphorylation (Figure 2.6c). 
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2.6 Discussion and Outlook 
The reliable production of all major mammalian PP-InsPs on a 100 mg scale is 
not limited to 13C-labeled compounds but is, of course, also amenable for 
unlabeled material as well. The newly found accessibility to PP-InsPs will enable 
the research community to pursue new avenues in their research that have so far 
been inaccessible due to a lack of the required materials. High-throughput screens 
for IP6K and PPIP5K inhibitors are now, for example, possible. Another pressing 
question is the existence of additional PP-InsP phosphatases. Only now is enough 
substrate available to test a large array of potential candidates and define their 
substrate specificity. Recently, a study described a group of InsP6 and 5PP-InsP5 
interacting proteins in yeast.25 In order to elucidate how these interactions 
influence the protein’s activity sufficient PP-InsP quantities are needed.  
The main application for 13C-labeled myo-inositol and PP-InsPs, however, will be 
in NMR spectroscopy. Replacing radioactive inositol with [13C6]myo-inositol in cell 
labeling experiments would be a great improvement as 13C is a benign label. 
Furthermore, the samples could be analyzed without the need for a separation 
step, possibly capturing interactions that are otherwise inaccessible.  
13C-PP-InsPs can be a valuable tool to follow reactions in vitro, as well. 
Currently, no method is capable to replace a radioactive assay in all biochemical 
applications. Here, 13C-PP-InsP could provide an alternative approach, be it for 
kinetic studies or in a binding assay. 
The main bottlenecks in the presented methodology are the large amounts of 
IP6KA and especially PPIP5K2 that are required. However, the proteins express 
well and groups with biological experience will have no problem obtaining 
sufficient amounts of these proteins.  
During the method development, we realized that clean InsP6 starting material is 
essential to obtaining pure product. All commercially available InsP6 that we tested 
was not clean enough to be used as starting material and so we prepared it 
ourselves. Although the synthesis is not difficult, it requires standard chemistry 
equipment and is low yielding, making it inaccessible for biological groups. These 
problems could be circumvented with pure commercially available InsP6. I did not 
test all available vendors and hence, give no final recommendation. 
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2.7 Methods 
General Information 
All chemicals were purchased from Sigma Aldrich, VWR, Carl Roth, Thermo 
Fisher Scientific, Alfa Aesar, TCI and used without further purification unless 
stated otherwise. All dry solvents were purified using a solvent purification system 
MBRAUN MB-SPS-5 by passing through activated alumina columns. Deuterated 
solvents were purchased from Euriso-Top. The C18 Sep-Pak columns were 
purchased from Waters. Telos® was ordered from Kinesis. Normal phase flash 
chromatography was performed using analytical grade solvents and silica gel from 
VWR (40-63 µm) as stationary phase. Automated flash chromatography was 
performed using gradient grade solvents on a CombiFlash® Rf from Teledyne Isco 
using prepacked CombiFlash® columns (40-63 µm). Reversed phase flash 
chromatography was performed on C18 reversed phase silica gel from Teledyne 
Isco (40-63 µm) as stationary phase. LC-MS analysis was carried out with an 
Agilent 1260 Infinity Binary LC system connected to an Agilent 6130 Quadrupole 
LC/MS system with a ZORBAX Rapid Resolution HT Narrow Bore SB-C18 1.8 μm 
column (2.1 x 50mm) at 30 °C using API-ESI (atmospheric pressure ionization-
electrospray) in positive ion mode. The eluent consisted of 10% ACN in water with 
0.1% formic acid at 0.7 mL/min flow rate.  
NMR spectra were recorded on Bruker spectrometers operating at 300 or 600 
MHz for proton nuclei, 75 or 151 MHz for carbon nuclei or 122 and 244 MHz for 
phosphorous nuclei. NMR data are given as follows: chemical shift δ in ppm 
(multiplicity, coupling constant(s) J Hz, relative integral) where multiplicity is 
defined as: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad 
or combinations of the above. The software used to control the spectrometer was 
topspin 3.5 pl6. Temperature had been calibrated using d4-methanol and the 
formula of Findeisen et al.26  
High-resolution mass spectrometer was performed by direct inject on an 
OrbitrapTM Q-Exactive mass spectrometer (Thermo Fisher Scientific).  
For the purification via FPLC an NGC QuestTM 10 Chromatography System from 
Bio-Rad was used with an integrated NGCTM Sample Pump Module and a 
BioFracTM Fraction Collector. For the spin filtration Amicon Ultra 0.5 mL centrifugal 
filters with a cut off of 10 kDa or 3 kDa from Merck Millipore were used.  
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Recombinant Protein Expression 
 
Inositol phosphate Synthase (IPS) 
The IPS-gene from A. fulgidus cloned into a pET23a vector (Prof. Helena 
Santos, Universidade Nova de Lisboa)27 was transformed into E. coli BL21(DE3). 
Two 0.8 liter overnight cultures (37 °C) in Terrific Broth (TB) supplemented with 
Ampicillin were each diluted with 400 mL TB, prewarmed to 37 °C. After 30 min 
the expression was induced with 0.25 mM IPTG. After 4 hours the cells were 
harvested by centrifugation (3,000 g for 10 min at 4 °C) and washed with ice cold 
water. The pellet was stored at -80 °C until further use. 
The frozen cells were resuspended in lysis buffer (50 mM Tris HCl pH 8, 250 
mM NaCl). For 1 g cell pellet wet weight, 5 mL lysis buffer was used. The cell 
suspension was supplemented with lysozyme and DNase I, and incubated for 15 
min on ice. The cells were lysed with a Microfluidizer™ LM10 at 15,000 psi with 
five iterations. The lysate was clarified by centrifugation (30,000 g for 30 min at 4 
°C). The supernatant was incubated for 30 min at 80 °C and the precipitate was 
removed by centrifugation (30,000 g for 30 min at 4 °C). The volume of the heat-
treated supernatant was reduced to 22 mL with spin filtration (Amicon® Ultra 15 
mL 10K) and the solution was dialyzed against lysis buffer overnight. The protein 
solution was adjusted to 33 % (v/v) glycerol, aliquoted, frozen in liquid nitrogen, 
and stored at -80 °C. 
 
Inositol hexakisphosphate kinase A (IP6KA) 
The codon optimized IP6KA-gene from E. histolytica was subcloned from a 
pDest-566 vector (a kind gift from Stephen B. Shears)28 into a pET15b plasmid 
using NdeI and BamHI restriction sites that were introduced by PCR (forward 
primer (NdeI): GGCAGCCATATGAACACGAAAATCAAACGCG, reverse primer 
(BamHI): GCAGCCGGATCCTTACAGTGACTTAAATTCGTTTTCG). The resulting 
pET15b-IP6KA plasmid was transformed into E. coli BL21 Arctic Express (DE3) 
and an overnight culture was diluted into 1 L of TB medium supplemented with 
Ampicillin to a final density of OD600 0.1. The cells were grown for 6 h at 37 °C. 
The culture was then switched to 18 °C for 30 min before induction with 0.1 mM 
IPTG for 18 hours. The cells were harvested by centrifugation (3,000 g for 10 min 
at 4 °C) and washed with ice cold water. The cell pellet was resuspended in lysis 
 30 
 
buffer (25 mM Tris HCl pH 7.4, 500 mM NaCl, 50 mM imidazole). For 1 g wet 
weight 10 mL lysis buffer was used. The cell suspension was supplemented with 
lysozyme, DNase I, and 1 tablet cOmpleteTM protease inhibitor (Roche), and 
incubated for 15 min on ice. The cells were lysed with a microfluidizer™ LM10 at 
15,000 psi with five iterations. The lysate was clarified by centrifugation (30,000 g 
for 30 min at 4 °C). The supernatant was filtered (VWR® vacuum filter, PES 0.45 
µm), and loaded onto a Ni-NTA column (GE, 5 mL, HiTrap IMAC HP) equilibrated 
with lysis buffer with a flowrate of 2.5 mL/min. The column was washed with lysis 
buffer until the absorption was constant. IP6KA was eluted with a gradient of 
elution buffer (25 mM Tris HCl pH 7.4, 200 mM NaCl, 500 mM imidazole) in lysis 
buffer from 0-100 % over 10 CV. 1.5 mL fractions were collected. The fractions 
containing IP6KA were concentrated by spin filtration (Amicon® Ultra 0.5 mL 10K) 
and dialyzed overnight against dialysis buffer (20 mM Tris HCl pH 7.4, 200 mM 
NaCl, 1 mM DTT). The following day the protein was adjusted to 25 % glycerol, 
frozen in liquid nitrogen and stored at -80 °C. 
 
Synthesis of [13C6]myo-inositol 
 
 
 
The following stock solutions were prepared: 
Hexokinase stock solution: 1000 U/mL in 50 mM citrate pH 7, 10 mM MgCl2, 1 
mg/mL BSA. 
Creatine kinase stock solution: 350 U/mL in 200 mM MOPS pH 6.5, 20 mM MgCl2, 
20 mM DTT. 
Inositol phosphate synthase stock solution: 4 mg/mL in 20 mM Tris HCl pH 7.4, 
200 mM NaCl, 1 mM DTT. 
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Alkaline phosphatase stock solution: 100 U/mL, 10 mM Tris pH 8.5, 5 mM MgCl2, 
0.2 mM ZnCl2, 50 % (v/v) glycerol. 
 
A solution containing D-[13C6]glucose (2) (83 mM, 1000 mg, 5.4 mmol), MOPS 
(100 mM, pH 6.5), creatine phosphate (87 mM), ATP (1 mM), DTT (20 mM) and 
MgCl2 (20 mM) in MilliQ® water (65 mL total reaction volume) was prepared and 
evenly split (32.5 mL each) into two 50 mL conical tubes. Hexokinase (1 U/mL) 
and creatine kinase (1.75 U/mL) were added and the reaction incubated at 30 °C 
overnight. The resulting solution was monitored by TLC 
(MeOH:H2O:NH4OH:AcOH, 50:30:15:5; stained by KMnO4 or excessive heating) 
and upon completion diluted 5-fold with 320 mL of water. An anion-exchange 
column (DOWEX® 1X8) was equilibrated with 1 M (NH4)HCO3 and washed with 
water. The reaction mixture was loaded onto the column followed by washing with 
water to remove unreacted 2. [13C6]glucose-6-phosphate (3) was eluted by 0.1 M 
(NH4)2CO3 and lyophilized to obtain the product 3 in combination with high amount 
of salts (4 g) as a white solid.  
The product/salt mixture was redissolved in 40 mL MilliQ® water and added to a 
solution of Tris (50 mM, pH 8.0), NAD+ (0.5 mM), NaCl (50 mM) and MgCl2 (2 mM) 
in MilliQ® (196 mL total reaction volume). The pH was adjusted to 8.0, if 
necessary, and the mixture was evenly split (49 mL each) into four 50 mL conical 
tubes. Recombinantly expressed inositol-3-phosphate synthase (IPS) (500 µL of 4 
mg/mL stock) was added to each tube and the reaction mixture was incubated at 
85 °C monitoring conversion by NMR. After 4 h, NAD+ (10 mg, 0.8 mM total) and 
IPS (500 µL, 4 mg/mL) were added to each tube and the mixture was incubated 
for additional 4 h at 85 °C. After full conversion of 3 into [13C6]myo-inositol-3-
phosphate (4) was observed by 13C NMR the reaction mixture was directly used 
for the subsequent dephosphorylation reaction.  
For the dephosphorylation reaction, the 200 mL reaction mixture was split 
evenly across 5 conical tubes (40 mL each). For a total reaction volume of 50 mL, 
glycine (50 mM, pH 9.8) was added and the pH adjusted to 9.8. ZnCl2 (0.25 mM) 
and alkaline phosphatase (0.5 U/mL) were added and the solution was filled up to 
50 mL with MilliQ® water. After incubation at 35 °C overnight, all tubes were 
combined (250 mL total) and diluted with 300 mL MilliQ® water and the reaction 
mixture was applied to an ion exchange column (DOWEX® 1X8 in HCO3
- form). 
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The flow-through was collected and lyophilized to afford [13C6]myo-inositol (1) with 
salts (7.5 g) as a brown solid which was directly used for the acetylation reaction. 
 
 
[13C6]Inositol hexakisacetate (S1) 
The crude material of 1 (7.5 g) was suspended in pyridine (161 mL) and treated 
with acetic anhydride (68.5 mL) at 120 °C overnight. The black solution was 
concentrated to minimize the amount of pyridine, re-dissolved in DCM (500 mL), 
and 1 M HCl was added. The resulting suspension was filtered and the filter 
washed with DCM and water. All filtrates were combined and organic and aqueous 
phase were separated. (Note: Phase separation is hard to see because of the 
black solution so use a flash light to find the separation layer.) The aqueous layer 
was extracted twice with DCM and the combined organic layers were washed with 
1 M NaHCO3. The aqueous layer was washed twice with DCM and the combined 
organic layers were washed with brine, dried with Na2SO4 and concentrated under 
reduced pressure. The residue was immobilized on Telos® and purified by column 
chromatography on silica gel changing the eluent step wise (hexane:EtOAc, 10:1 
→ 5:1 → 1:1 → 1:2) assisted by analysis of the fractions by LCMS to afford 
compound S1 (1200 mg, 2.7 mmol) as a white solid in 50% overall yield from 2. 
1H NMR (600 MHz, CDCl3) δ 5.79 – 5.54 (m, 1.5H), 5.53 – 5.32 (m, 1.5H), 5.32 – 
5.12 (m, 1.5H), 5.11 – 4.82 (m, 1.5H), 2.20 (s, 3H), 2.01 (s, 3H), 2.01 (s, 6H), 2.00 
(s, 6H). 
13C NMR (151 MHz, CDCl3) δ 169.94, 169.81, 169.56, 71.68 – 70.65 (m), 70.11 – 
69.15 (m), 69.11 – 67.90 (m), 20.89, 20.69, 20.60. 
HRMS (ESI/Orbitrap) m/z: [M + K]+ calcd. for C12
13C6H24KO12 477.1101; Found 
477.1091. 
 
 
 33 
 
 
[13C6]myo-Inositol (1) 
To a solution of S1 (1200 mg, 2.7 mmol) in methanol (249 mL), 5.4 M NaOMe in 
MeOH (3.35 mL, 18.1 mmol) was added and the reaction was left to stir for 2 
hours. The resulting suspension was neutralized by the addition of DOWEX 50W x 
8 (H+ form) followed by filtration. The residue was washed with methanol (100 mL) 
and water (100 mL) to dissolve all precipitated [13C6]myo-inositol and the filtrate 
was evaporated. The resulting solids were redissolved in H2O and precipitated by 
the addition of MeCN. Subsequently, the solids were redissolved in H2O and 
lyophilized to afford 1 (505 mg, 2.7 mmol) as white solid in 99% yield. 
1H NMR (600 MHz, D2O, pD 7.0) δ 4.29 – 4.14 (m, 0.5H), 4.03 – 3.90 (m, 0.5H), 
3.82 – 3.60 (m, 2H), 3.59 – 3.34 (m, 2.5H), 3.25 – 3.12 (m, 0.5H). 
13C NMR (151 MHz, D2O, pD 7.0) δ 74.96 – 73.80 (m), 72.86 – 71.71 (m), 71.60 – 
70.50 (m). 
HRMS (ESI/Orbitrap) m/z: [M – H]– Calcd for 13C6H11O6 185.0762; Found 
185.0814. 
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Chemical synthesis of [13C6]inositol polyphosphates 
 
Synthesis of xylyl phosphoamidite 
 
 
N,N-diethylaminodichlorophosphine (S2) 
N,N-diethylaminodichlorophosphine was synthesized according to a procedure 
of Drent and coworkers.29 S2 was obtained in 68% yield (12.9 g, 74.37 mmol) in 
good purity. 1H-, 13C- and 31P NMR are in agreement with the literature procedure.  
 
 
Xylyl phosphoramidite (S3) 
Xylyl phosphoamidite was synthesized according to a modified procedure of 
Gregory and coworkers30. S2 (11.1 g, 63.79 mmol) was dissolved in dry THF (425 
mL) and cooled to -78 °C. A solution of triethylamine (12.9 g, 17.8 mL, 127.59 
mmol) and phenyldimethanol (8.8 g, 63.79 mmol) in dry THF (425 mL) was 
prepared and added to the stirring reaction mixture with a dropping funnel over 30 
min. The cooling was removed and the reaction left to stir overnight at room 
temperature. The resulting precipitates were removed by filtration and washed with 
dry THF (2 × 100 mL) and the filtrate was concentrated to 500 mL. TEA (5 mL) 
was added to the solution and it was passed through a silica plug (equilibrated 
with 1% TEA in dry THF). Subsequently, 1% TEA in THF (2.0 L) was passed 
through the silica plug and the combined organic fractions were concentrated to 
afford the product (14.9 g, 62.09 mmol) as colorless oil in 97 % yield. The product 
can be stored at -20 °C under N2 for several months. 
1H-, 13C- and 31P NMR are in 
agreement with the literature procedure.  
  
 35 
 
Synthesis of [13C6]inositol hexakisphosphate (6) 
 
 
Xylyl protected [13C6]inositol hexakisphosphate (S4) 
Xylyl protected [13C6]inositol hexakisphosphate (S4) was synthesized according 
to a modified procedure of Podeschwa and coworkers31. Under nitrogen 
atmosphere a suspension of 1 (100 mg, 0.54 mmol) and S3 (900 mg, 3.76 mmol) 
in dry DCM (38.65 mL) was prepared and sonicated for 1 min. 1H-tetrazole in 
anhydrous MeCN (14.33 mL, 6.45 mmol, 0.45 M) was added and the solution was 
stirred at rt overnight. For workup the solution was cooled to -40 °C and an 
anhydrous solution of mCPBA in DCM (30 mL dried with Na2SO4) was added. The 
solution was allowed to warm to rt, and the stirring was continued for another hour. 
The reaction mixture was diluted with DCM (300 mL) and washed consecutively 
with aqueous sodium bisulfite (20%, 2 × 50 mL), saturated NaHCO3 (3 × 100 mL), 
and then with brine. After evaporation of the solvents, the crude was immobilized 
on Telos® and purified by CombiFlash® chromatography on silica gel (12 g 
column, gradient: 0% → 2% → 4% → 10% MeOH in DCM) and afforded the 
product (221 mg, 0.173 mmol) as a white solid in 32% yield. 
1H NMR (600 MHz, Chloroform-d) δ 7.60 – 7.49 (m, 18H), 7.44 (d, J = 7.7 Hz, 6H), 
5.93 (dd, J = 13.8, 9.5 Hz, 2.5H), 5.84 (dd, J = 13.7, 9.1 Hz, 2H), 5.79 – 5.70 (m, 
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6H), 5.66 (s, 0.5H), 5.55 (dd, J = 13.9, 12.4 Hz, 3H), 5.50 – 5.16 (m, 15H), 5.12 (s, 
1H). 
13C NMR (151 MHz, Chloroform-d) δ 135.94, 135.91, 135.73, 135.69, 135.52, 
134.62, 129.72, 129.60, 129.47, 129.45, 129.42, 129.40, 129.39, 129.36, 129.19, 
129.13, 78.48 – 76.20 (m), 73.92 (dd, J = 43.9, 34.0 Hz), 69.84, 69.79, 69.68, 
69.62, 69.57, 69.51, 69.45. 
31P NMR (122 MHz, Chloroform-d) δ -2.80, -3.57, -4.48, -4.71.  
HRMS (ESI/Orbitrap) m/z: [M + H]+ Calcd for C48
13C6H54O24P6 1279.1705; Found 
1279.1676. 
 
 
[13C6]inositol hexakisphosphate (6) 
[13C6]inositol hexakisphosphate (6) was synthesized according to a modified 
procedure of Godage and coworkers32. Compound S4 (148 mg 0.12 mmol) was 
dissolved in methanol (10.53 mL) and water (2.63 mL) and 20% Pd(OH)2/C (50% 
wetted with water) (68 mg, 0.49 mmol) was added. The resulting suspension was 
stirred at room temperature overnight under hydrogen atmosphere. The reaction 
mixture was passed through a PTFE syringe filter and the filtrate was evaporated 
under reduced pressure. The free acid was treated with NaOH (1 M) to afford the 
dodecasodium salt of 6 as a white solid (136 mg, 0.10 mmol, 66 w/w%) in 83% 
yield. 
1H NMR (600 MHz, Deuterium Oxide, pD 7.0) δ 5.01 – 4.90 (m, 0.5H), 4.71 – 4.63 
(m, 0.5H), 4.48 – 4.34 (m, 1H), 4.22 – 4.04 (m, 2.5H), 3.95 – 3.78 (m, 1.5H). 
13C NMR (151 MHz, Deuterium Oxide, pD 7.0) δ 79.99 (d, J = 35.7 Hz), 78.52 (t, J 
= 40.0 Hz), 77.60 – 74.58 (m). 
31P NMR (122 MHz, Deuterium Oxide, pD 7.0) δ 1.99, 1.04, 0.77. 
HRMS no ion detected. 
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Synthesis of and [13C6]inositol pentakisphosphate 
 
 
[13C6]inositol-(1,3,5)-orthobenzoate ester (S5) 
[13C6]inositol-(1,3,5)-orthobenzoate (S5) ester was synthesized according to a 
modified procedure of Godage and coworkers32. A suspension of 1(1.045 g, 5.61 
mmol) and CSA (26.08 mg, 0.11 mmol) in DMSO (3.74 mL) was heated to 80 °C 
under vacuum (Rotovap, 30-40 mbar) to remove residual water. Upon the addition 
of trimethyl orthobenzoate (1.125 g, 6.17 mmol, 1.061 mL), the mixture was left at 
80 °C under vacuum (Rotovap, 30-40 mbar) until the suspension became clear. 
The resulting solution was quenched with TEA (62.5 mg, 0.62 mmol, 86 µL). 
(Note: Quenching of acid is highly important to assure the stability of the formed 
orthoester during the workup.) The product was slowly precipitated through the 
addition of water (16 mL) at 4 °C and the solids were filtered and washed with ice 
cold water 3 times. The mother lye was combined with the washings and applied 
to reversed phase chromatography changing the eluent step wise (5 % → 25 % → 
50 % MeCN in H2O) to separate residual product from DMSO. The product 
containing fractions were lyophilized and the precipitates were dissolved in 50 % 
MeCN in H2O and lyophilized to afford the product S5 (1.300 g, 4.78 mmol) as 
white solid in 85% yield. 
1H NMR (600 MHz, Methanol-d4) δ 7.71 – 7.64 (m, 2H), 7.42 – 7.30 (m, 3H), 4.70 
(s, 1H), 4.45 (s, 2.5H), 4.37 (s, 0.5H), 4.18 (s, 1.5H), 4.13 (s, 0.5H). 
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13C NMR (151 MHz, Methanol-d4) δ 130.12, 128.58, 126.74, 77.50 (t, J = 37.2 Hz), 
71.63 (t, J = 37.7 Hz), 68.98 (t, J = 37.7 Hz), 60.20 (t, J = 36.8 Hz). 
HRMS no ions detected. 
 
 
2-Benzoyl [13C6]inositol (S6) 
[13C6]benzoyl inositol (S6) was synthesized according to a procedure of Godage 
and coworkers32. A mixture of TFA (1.8 mL) and water (180 µL) was added to S5 
(300 mg, 1.1 mmol) and the solution was stirred for 1 h and the conversion was 
followed by TLC (100 % EtOAc; starting material Rf 0.6; product Rf 0.0). The 
reaction mixture was then co-evaporated with water in vacuo, redissolved in water 
and lyophilized to obtain the product S6 (314 mg, 1.08 mmol) as a white solid in 
quantitative yield. 
1H NMR (600 MHz, Deuterium Oxide, pD 7.0) δ 8.10 (d, J = 7.8 Hz, 2H), 7.74 (d, J 
= 7.5 Hz, 1H), 7.59 (t, J = 7.7 Hz, 2H), 5.86 (s, 0.5H), 5.60 (s, 0.5H), 4.02 – 3.89 
(m, 2H), 3.78 – 3.66 (m, 2H), 3.58 – 3.51 (m, 0.5H), 3.36 – 3.28 (m, 0.5H). 
13C NMR (151 MHz, Deuterium Oxide, pD 7.0) δ 170.73, 136.84, 132.46, 131.52, 
77.85 (t, J = 38.6 Hz), 77.09 (t, J = 38.6 Hz), 75.62 (t, J = 38.8 Hz), 72.63 (td, J = 
38.8, 6.6 Hz). 
HRMS (ESI/Orbitrap) m/z: [M + H]+ calcd. for C7
13C6H17O7 291.1170; Found 
291.1166. 
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Xylyl protected [13C6]benzoyl inositol (S7) 
Xylyl protected [13C6]benzoyl (S7) inositol was synthesized according to a 
procedure of Godage and coworkers32. To a solution of S6 (200 mg, 0.7 mmol) 
and 5-phenyltetrazole (1.01 g, 6,89 mmol) in dry DCM (4.9 mL) under nitrogen 
atmosphere was added S3 (1.24 g, 5.17 mmol). The suspension was sonicated (1 
min) and further stirred overnight at rt. The reaction mixture was cooled to -40 °C, 
and mCPBA (1.70 g, 6.89 mmol) was added portion-wise while stirring. The 
cooling bath was removed, and the mixture was allowed to reach rt and diluted 
with DCM (50 mL), washed with 10% sodium sulfite solution (2 × 100 mL), dried 
and solvent evaporated in vacuo. The crude was immobilized on Telos® and 
purified by CombiFlash® chromatography on silica gel (120 g column, gradient: 
1% → 4% → 10% MeOH in DCM) to afford the product S7 (651 mg, 0.54 mmol) 
as white solid in 79% yield 
1H NMR (600 MHz, Chloroform-d) δ 8.06 (d, J = 7.1 Hz, 2H), 7.61 – 7.53 (m, 1H), 
7.49 – 7.45 (m, 2H), 7.43 – 7.35 (m, 10H), 7.35 – 7.30 (m, 6H), 7.29 – 7.27 (m, 
1H), 7.26 – 7.23 (m, 2H), 6.53 (s, 0.5H), 6.27 (s, 0.5H), 5.64 (ddd, J = 17.9, 13.9, 
8.1 Hz, 4H), 5.58 – 5.47 (m, 3H), 5.41 (dd, J = 13.7, 9.4 Hz, 2H), 5.27 (s, 1H), 5.21 
(dd, J = 13.5, 10.9 Hz, 3.5H), 5.16 (d, J = 9.8 Hz, 1H), 5.12 (d, J = 8.7 Hz, 1H), 
5.05 (ddd, J = 22.1, 13.8, 5.8 Hz, 8H), 4.96 (s, 1.5H). 
13C NMR (151 MHz, Chloroform-d) δ 78.00 – 76.46 (m), 74.25 (td, J = 38.4, 36.8, 
6.5 Hz), 70.59 (t, J = 38.5 Hz). 
31P NMR (122 MHz, CDCl3) δ -3.32, -4.25, -4.90. 
HRMS (ESI/Orbitrap) m/z: [M + Na]+ Calcd for C47
13C6H51NaO22P5 1223.1613; 
Found 1223.1613. 
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Benzoyl [13C6]inositol pentakisphosphate (S8) 
[13C6]benzoyl inositol pentakisphosphate (S8) inositol was synthesized 
according to a procedure of Godage and coworkers32. S7 (50 mg, 0.04 mmol) was 
dissolved in methanol (3.8 mL), and water (0.95 mL) and 20% Pd(OH)2/C (50% 
wetted with water) (25 mg, 0.18 mmol) were added. The resulting suspension was 
stirred at rt overnight under hydrogen atmosphere. The catalyst was filtered 
through a PTFE syringe filter, and the filtrate neutralized by the addition of 1 M 
Et3NHCO3 until the pH 7.5 was reached. Lyophilization afforded the product S8 (50 
mg, 0.037 mmol, 8 × EtN3 salt) as white solid in 88% yield. The amount of the 
TEA-counter ion was determined by NMR spectroscopy. 
1H NMR (600 MHz, Deuterium Oxide, pD 7.0) δ 8.19 (dd, J = 8.2, 1.9 Hz, 2H), 7.74 
(t, J = 7.2 Hz, 1H), 7.61 (dd, J = 9.0, 6.6 Hz, 2H), 6.10 (s, 0.5H), 5.84 (s, 0.5H), 
4.58 – 4.45 (m, 2H), 4.39 (s, 0.5H), 4.27 (s, 1H), 4.16 (d, J = 11.1 Hz, 0.5H), 3.21 
(qd, J = 7.3, 2.5 Hz, EtN3), 1.30 (td, J = 7.3, 2.6 Hz, EtN3). 
13C NMR (151 MHz, Deuterium Oxide, pD 7.0) δ 77.65 (t, J = 39.7 Hz), 76.46 (t, J 
= 39.7 Hz), 73.93 (t, J = 38.6 Hz), 72.53 (t, J = 39.9 Hz), 46.60, 8.23. 
31P NMR (122 MHz, Deuterium Oxide, pD 7.0) δ 0.33, -0.00, -0.80. 
HRMS (ESI/Orbitrap) m/z: [M – 2H]2- calcd. for C7
13C6H19O22P5 343.9634; Found 
343.9954. 
 
 
[13C6]inositol pentakisphosphate (5) 
[13C6]inositol pentakisphosphate (5) was synthesized according to a procedure 
of Godage and coworkers32. Compound S8 (50 mg, 0.037 mmol) was dissolved in 
concentrated aqueous ammonia solution (2.0 mL) and heated at 60 °C overnight 
in a Pyrex pressure tube. After evaporation of the solution under vacuum, the 
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residue was dissolved in water and the benzamide byproduct was removed by 
washing with DCM. The ammonium salt of the product was obtained by 
evaporation of the ammonia and converted into the free acid by quick filtration 
(Note: Prolonged exposure causes phosphoryl group migration.) through DOWEX 
50W x 8 (H+ form) (10-fold molar excess, previously washed with MilliQ® water) 
and then to its hexasodium salt by titration to pH 7.40 with 0.1 M sodium hydroxide 
solution. Lyophilization afforded the product 5 (17 mg, 0.024 mmol) as white solid 
in 65% yield. 
1H NMR (300 MHz, Deuterium Oxide, pD 7.5) δ 4.72 – 4.53 (m, 1.5H), 4.47 – 4.25 
(m, 1.5H), 4.24 – 4.02 (m, 1.5H), 3.96 – 3.74 (m, 1.5H). 
13C NMR (75 MHz, Deuterium Oxide, pD 7.5) δ 78.28 – 74.98 (m), 73.92 (t, J = 
37.7 Hz), 70.68 (t, J = 37.6 Hz). 
31P NMR (122 MHz, D2O, pD 7.5) δ 1.49, 1.23, 0.86. 
HRMS no ions detected. 
 
Enzymatic synthesis of [13C6]inositol pyrophosphates 
 
Synthesis of [13C6]5-diphosphoinositol pentakisphosphate (7) 
 
The following stock solutions were prepared: 
Creatine kinase stock solution: 350 U/mL creatine kinase in 200 mM MOPS pH 
6.5, 20 mM MgCl2, 20 mM DTT 
IP6KA stock solution: 10 mg/mL IP6KA in 20 mM Tris HCl pH 7.4, 200 mM NaCl, 1 
mM DTT 
ATP stock solution: 50 mM in MilliQ® water pH 6.4; (Note: Concentration was 
determined via UV-Vis analysis at 259 nm; ε259 = 15.4 E/mmol/cm). 
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A solution of 6 (dodecasodium salt, 70 mg, 250 µM, 66 w/w%), MES (20 mM, pH 
6.4), NaCl (50 mM), ATP (disodium salt, 2 mM), creatine phosphate (5 mM), MgCl2 
(7 mM), DTT (1 mM) in 199 mL MilliQ® water was prepared. The pH was adjusted 
to 6.4 and the mixture was split into four 50 mL conical tubes. The individual tubes 
were then equilibrated to 37 °C within 30 min without shaking. IP6KA (1 µM) and 
creatine kinase (1 U/mL) were added, the tube was gently inverted several times 
to homogenize and left to react for exactly 45 min without shaking. (Note: The 
correct temperature was essential to assure full conversion of the starting material 
within 45 min. Prolonged reaction times above 1 h led to side reactions. However, 
the speed of the reaction will depend on the batch and quality of the recombinantly 
expressed IP6KA.) 
Purification: The reaction was stopped by cooling the reaction mixture down to 4 
°C within 5 min with the help of a dry ice isopropanol bath. Four short C18 
columns (SepPak V C18 500 mg) were each washed and equilibrated with 9 mL 
MeCN, then 9 mL H2O. To remove protein, the reaction mixture was filtered 
through the SepPak columns (1 column per 50 mL reaction) and each column was 
washed with 20 mL water. The flow through was combined (~280 mL) and the pH 
adjusted to 9.0-9.2 by dropwise addition of a 10 M NaOH-solution (roughly 180 
µL). 2.3 mL of a 1 M MgCl2 solution was added which led to precipitation of InsPs 
as magnesium complex. The suspension was left shaking at room temperature 
overnight to facilitate complete precipitation. The suspension was centrifuged (5 
min at 3000 g), the supernatant removed and the precipitate washed 3 times with 
15 mL MgCl2 solution (8 mM, pH 9 adjusted with NaOH)  
The precipitate was resuspended in 10 mL NH4HCO3 buffer (10 mM, pH 8) and 
mixed with Amberlite IRC-748 (10 mL wetted bed volume, pre-equilibrated with 
NH4HCO3, pH 8) until the precipitate dissolved. (Note: The Amberlite resin should 
be washed with 500 mL of MeOH and 500 mL of H2O before use.) The buffer/resin 
suspension was added to a short Amberlite IRC-748 column (5 mL bed volume, 
pre-equilibrated with NH4HCO3, pH 8) to remove excess Mg
2+. The product was 
flushed through the column with 50 mL water and all eluents were collected and 
lyophilized to afford the ammonium salt of the product (100 mg, 0.14 mmol, 35.5 
w/w%) as white solid in quantitative yield. 
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1H NMR (600 MHz, Deuterium Oxide, pD 7.5) δ 5.05 – 4.95 (m, 0.5H), 4.69 – 4.58 
(m, 1H), 4.49 – 4.36 (m, 1.5H), 4.35 – 4.26 (m, 1H), 4.25 – 4.15 (m, 0.5H), 4.12 – 
4.00 (m, 1H). 
13C NMR (151 MHz, Deuterium Oxide, pD 7.5) δ 80.74 – 79.46 (m), 79.32 – 77.17 
(m), 76.03 (t, J = 38.7 Hz). 
31P NMR (243 MHz, D2O) δ -1.45, -2.00, -2.45, -10.32, -13.41. 
HRMS no ions detected. 
 
Synthesis of [13C6]1,5-bisdiphosphoinositol tetrakisphosphate (8) 
 
MilliQ® water was prewarmed to 37 °C by incubation in a water bath. A solution of 
5PP-InsP5 (250 µM, 100 mg based on free acid 726.9 g/mol), MES (20 mM, pH 
6.4), NaCl (250 mM), ATP (disodium salt, 2 mM), creatine phosphate (5 mM), 
MgCl2 (5 mM), DTT (1 mM) in 715 mL prewarmed MilliQ® water was prepared in a 
1 L Schott bottles and incubated in the water bath at 37 °C for 10 min. PPIP5K2KD 
(1.5 µM) and creatine kinase (1 U/mL) were added and bottle gently inverted 
several times to homogenize and left to react overnight for 5.5 h without shaking. 
Purification: The reaction was stopped by cooling the reaction mixture down to 4 
°C within 5 min with the help of a dry ice isopropanol bath. A fritted filter was 
loaded with 6 g of C18 reversed phase silica gel suspended in MeCN and sand 
was added on top. The C18 plug was washed with 30 mL MeCN and 30 mL H2O 
and the complete reaction mixture was passed through the filter under vacuum. 
The C18 plug was washed with 2 × 30 mL H2O and all the combined flow through 
was supplemented with 12.5 mM MgCl2. The pH was adjusted to 8.8–9.0 by drop 
wise addition of 10 mM NaOH solution which leads to precipitation of the PP-InsPs 
as magnesium complex within 1 h at room temperature. (The precipitation can 
also be performed overnight at room temperature.) The suspension was collected 
in 2 canonical 50 mL tubes by centrifugation (2 min at 3000 g) and the supernatant 
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was removed. The precipitates of each tube were washed 3 times with 15 mL 
MgCl2 solution (8 mM, pH 9 adjusted with NaOH). 
The precipitate of each tube was resuspended in 15 mL NH4HCO3 buffer (10 mM, 
pH 8) and vortexed with Amberlite® IRC-748 (15 mL wetted bed volume, pre-
equilibrated with NH4HCO3, pH 7.5–8) until the precipitate dissolved. The 
buffer/resin suspension of each tube was added to a short Amberlite® IRC-748 
column (5 mL bed volume, pre-equilibrated with NH4HCO3, pH 8) to remove 
excess Mg2+. The product was flushed through the column with 40 mL H2O and all 
eluents were collected, combined and lyophilized in a round-bottom flask to afford 
the ammonium salt of the product as white solid. The solids were dissolved in D2O 
and the concentration of the solution was determined by NMR against a standard 
(phosphonoacetic acid) to determine yield and purity: 12 mL of 12.7 mM solution 
were obtained which corresponds to 111 mg (77% yield, purity > 95%) 1,5(PP)2-
InsP4 based on the free acid 805.9 g/mL.  
1H NMR (600 MHz, Deuterium Oxide) δ 5.01 (d, J = 9.6 Hz, 1H), 4.55 (p, J = 9.9 
Hz, 2H), 4.36 (q, J = 9.8 Hz, 1H), 4.25 (t, J = 9.4 Hz, 1H). 
31P NMR (243 MHz, Deuterium Oxide) δ 0.56, 0.33, -0.26, -1.04, -10.34 (dd, J = 
29.9, 19.2 Hz), -11.03 (dd, J = 60.0, 19.3 Hz). 
13C NMR (151 MHz, D2O) δ 77.42, 76.05, 75.53, 74.78, 73.53, 73.18. 
HRMS no ions detected. 
 
Synthesis of [13C6]1-diphosphoinositol pentakisphosphate (9) 
 
MilliQ® water was prewarmed to 37 °C by incubation in a water bath. A solution of 
InsP6 (250 µM, 100 mg based on free acid 647.9 g/mol), MES (20 mM, pH 6.4), 
NaCl (250 mM), ATP (disodium salt, 2 mM), creatine phosphate (5 mM), MgCl2 (6 
mM), DTT (1 mM) in 617 mL prewarmed MilliQ® water was prepared in a 1 L 
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Schott bottles and incubated in a water bath at 37 °C for 10 min. PPIP5K2KD (2 
µM) and creatine kinase (1 U/mL) were added and bottle gently inverted several 
times to homogenize and left to react overnight for 18 h without shaking.  
Purification: The reaction was stopped by cooling the reaction mixture down to 4 
°C within 5 min with the help of a dry ice isopropanol bath. A fritted filter was 
loaded with 6 g of C18 reversed phase silica gel suspended in MeCN and sand 
was added on top. The C18 plug was washed with 30 mL MeCN and 30 mL H2O 
and the complete reaction mixture was passed through the filter under vacuum. 
The C18 plug was washed with 2 × 30 mL H2O and all the combined flow through 
was supplemented with 12.5 mM MgCl2. The pH was adjusted to 8.8–9.0 by drop 
wise addition of 10 mM NaOH solution which leads to precipitation of the PP-InsPs 
as magnesium complex within 1 h at room temperature. (The precipitation can 
also be performed overnight at room temperature.) The suspension was collected 
in 2 canonical 50 mL tubes by centrifugation (2 min at 3000 g) and the supernatant 
was removed. The precipitates of each tube were washed 3 times with 15 mL 
MgCl2 solution (8 mM, pH 9 adjusted with NaOH). 
The precipitate of each tube was resuspended in 15 mL NH4HCO3 buffer (10 mM, 
pH 8) and vortexed with Amberlite® IRC-748 (15 mL wetted bed volume, pre-
equilibrated with NH4HCO3, pH 7.5–8) until the precipitate dissolved. The 
buffer/resin suspension of each tube was added to a short Amberlite® IRC-748 
column (5 mL bed volume, pre-equilibrated with NH4HCO3, pH 8) to remove 
excess Mg2+. The product was flushed through the column with 40 mL H2O and all 
eluents were collected, combined and lyophilized in a round-bottom flask. The 
resulting white solid was purified in 2 runs using a strong anion exchange column 
(HiPrepTM Q HP 16/10, GE Healthcare) and H2O as buffer A and 1 M NH4HCO3 as 
buffer B. The column was washed with 100% B and equilibrated at 1% B. The 
sample was dissolved and loaded in 1% B and, followed by a gradient from 1% to 
20% in 1 CV. The product was eluted in a gradient from 20%–40% over 10 CV. 
Fractions were analyzed by a metal dye detection assay33 in a 96-well plate format 
and product containing fractions were combined and lyophilized in a round-bottom 
flask. The solids were dissolved in D2O and the concentration of the solution was 
determined by NMR against a standard (phosphonoacetic acid) to determine yield 
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and purity: 20 mL of 5.3 mM solution were obtained which corresponds to 77 mg 
(68% yield, purity > 95%) 1PP-InsP5 based on the free acid 726.9 g/mol.  
1H NMR (600 MHz, Deuterium Oxide) δ 5.08 (d, J = 9.8 Hz, 1H), 4.40 (p, J = 9.7 
Hz, 2H), 4.21 (t, J = 9.8 Hz, 1H), 4.15 (q, J = 9.5 Hz, 1H), 4.09 (t, J = 9.2 Hz, 1H). 
13C NMR (151 MHz, D2O) δ 77.32, 76.11, 75.68, 75.58, 73.70, 73.08. 
31P NMR (243 MHz, Deuterium Oxide) δ 1.64, 0.90, 0.40, 0.32, -0.94, -8.70, -10.89 
(d, J = 18.7 Hz). 
HRMS no ions detected. 
 
Enzymatic synthesis of 5PP-InsP5-β
32P (10) 
 
Reaction conditions: 20 mM MES pH 6.4, 50 mM NaCl, 1 mM DTT, 5 mM creatine 
phosphate, 200 µCi ATPγ32P (6000Ci/mmol 10mCi/ml from Perkin Elmer), 0.2 mM 
ATP, 2 mM MgCl2, 0.3 µM IP6KA, 1 U/ml creatine kinase, 0.2 mM InsP6. 
Volume: 500 µl reaction 
time: 1 h for IP6KA at 37 °C. 
For Purification: The solution was centrifuged (2 min at 5000 g) to separate 
possible precipitates (with these conditions I usually don’t observe precipitation). 
Remove the supernatant and check if you have a precipitate with a geiger counter 
(this is recommended as the precipitate might not be visible). If you have a 
precipitate wash it with 0.2 ml water 3 times and add the washes to the 
supernatant. Keep the precipitate for combining it with the reaction solution after 
the C18 column. 
One short C18 column (SepPak Vac RC tC18 100 mg, Waters, 
WAT043410) was washed and equilibrated with 5 mL MeCN, then 5 mL H2O. The 
reaction mixture was filtered through the SepPak column and the column was 
washed with 0.25 mL water aliquots until no radioactivity (low radioactivity 
compared to the filtrate) remained on the column. The filtrate and the precipitate 
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from the previous step were combined and 0.25 M MgCl2 was added to a final 
concentration of 16 mM. The pH was adjusted to 8.5 - 9 by dropwise addition of a 
0.1 M NaOH-solution (the pH was checked with pH-stripes. The Solution is 
radioactive). The mixture is left at rt overnight to facilitate complete precipitation. 
The next day the suspension was centrifuged (5 min at 5000 g) and the 
supernatant was removed. The precipitate was washed three times in 0.25 mL 
MgCl2 solution (8 mM, pH 9 adjusted with NaOH) and the suspensions were 
centrifuged (5 min at 5000 g). The precipitate was resuspended in 0.1 mL 
NH4HCO3 buffer (10 mM, pH 8) and mixed with chelex 100 (0.3 mL wetted bed 
volume, pre-equilibrated with 10 mM NH4HCO3, pH 8, column: BD PP reactor 2 ml 
with PE frit) until the precipitate dissolved (this will take up to one hour). The 
buffer/resin suspension was added to a short chelex 100 column (1 mL bed 
volume, pre-equilibrated with 10 mM NH4HCO3, pH 8) to remove excess Mg
2+. 
The product was flushed through the column with water until no radioactivity 
remained on the column and the eluent was collected (you should have < 3 ml). To 
the solution 10X apyrase buffer and 4 U/ml apyrase (NEB) were added and the 
reaction was incubated overnight at rt. Another precipitation and chelation 
followed. The elution of the chelex column was collected and concentrated in a 
speed-vac to afford the ammonium salt of the product as a concentrated solution (I 
usually end up with 50-100 µl). 
 
Protein pyrophosphorylation 
The 15 µl reactions contained 25 mM Tris HCl pH 7.4, 50 mM NaCl, 6 mM 
MgCl2, 1 mM DTT, and 4 µg either pNSR1 or NSR1. If needed 500 U Casein 
kinase II (NEB) or 0.1 µCi ATPγ32P (6000 Ci/mmol, Perkin Elmer) was added. 
The reactions were started by the addition of 10 µl 5PP-InsP5-β
32P and the 
samples were incubated for 30 min at 45 °C. The reactions were quenched by the 
addition of 5 µl 4X Laemmli sample buffer and heating to 95 °C for 5 min. The 
samples were loaded onto an SDS-PAGE and resolved. The gel was fixed, 
stained with colloidal coomassie, and dried before the radioactivity was detected 
using a phosphor imager screen. 
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Chapter 3: Analysis of inositol phosphates in vitro 
and ex vivo by NMR spectroscopyg 
3.1 Introduction 
Biochemical analysis of PP-InsP metabolizing enzymes 
Small molecule networks play a crucial part in cell homeostasis. To better 
understand how the small molecules function in a biological context and to tie 
them to observable phenotypes, their concentrations and dynamics have to be 
measured. In order to fully comprehend the underlying mechansims, it is 
necessary to fully characterize the enzymes catalyzing the reactions that make up 
a particular pathway. For example, the ability of IP6Ks to directly respond to ATP 
availability is caused by its relatively high KM,ATP of about 0.5 mM, near 
physiological concentrations, highlighting the need to know these kinetic 
properties. For determining kinetic parameters of kinases two approaches are 
commonly pursued: measuring either the consumption of ATP or the conversion of 
substrate.  
ATP consumption can be detected by several methods, including coupling ATP 
turnover to NADH oxidation via pyruvate kinase and lactate dehydrogenase or by 
ADP-GloTM (Figure 3.1a,b).1 Such an approach, however, is problematic, as InsP- 
and PP-InsP kinases are known to possess an ATPase activity as well, uncoupling 
ATP consumption from product formation.2 This enzyme property mostly 
disqualifies the approach of ATP measurement. A better alternative is the direct 
monitoring of InsP conversion. In the past, this has been achieved by three 
different methods (Figure 3.1c-e). 
Radioactive labeling of InsPs with tritium (3H) provides a sensitive analytical 
handle that can be exploited by scintillation counting after SAX-HPLC separation 
                                                             
g
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Figure 3.1. Methods for the in vitro characterization of InsP kinases. (a) ATP-consumption can be 
measured by coupling the oxidation of NADH to the production of ADP. PK: pyruvate kinase, LDH: 
lactate dehydrogenase. (b) The amount of generated ADP can be determined by removing 
unreacted ATP, converting the ADP to ATP and quantifying it by bioluminescence. 
(c) Radioactively labeled InsPs can be resolved via SAX-HPLC and the amount of radioactivity in 
each fraction is analyzed. (d) Instead of a radioactive handle, the InsPs can be detected by a metal 
dependent dye. (e) InsPs are enriched with TiO2-beads from complex mixtures, subsequently 
resolved via PAGE, and detected by staining with toluidine blue. (f) 
13
C-labeled InsPs can be 
directly measured in complex samples using NMR spectroscopy.
 
(Figure 3.1c). This method has enabled seminal findings in the field but is 
dependent on dedicated radioactive HPLC equipment, a commitment not 
every group can make. Furthermore, the only supplier of [3H]InsPs has 
discontinued their distribution, rendering this method unavailable for most 
laboratories.  
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Research groups developed alternative methods to detect InsP conversion, one 
of which aimed to replace the radioactivity read-out with a more benign detection 
method while still retaining the SAX-HPLC based separation (Figure 3.1d). Mayr 
and co-workers exploited the metal chelation property of InsPs by using a metal 
dependent dye. This method is sensitive but suffers from high variability and has 
seen no use by the field.3 
Saiardi and coworkers, on the other hand, adapted high percentage 
polyacrylamide gels used in polyphosphate research for the analysis of PP-InsPs 
(Figure 3.1e). Here, the extracted InsPs and PP-InsPs have to be enriched over 
TiO2 beads, and are then resolved on a high-percentage polyacrylamide gel 
(PAGE) and stained by an cationic dye.4 Although the independence from 
radioactive tracers has allowed more laboratories to employ this approach, the 
lack of an InsP-specific analytical handle requires a more elaborate sample 
preparation and it is limited to the detection of only the most highly phosphorylated 
InsPs (InsP6 – InsP8). Furthermore, the limit of detection is not as good as for 
radioactive labeling. 
While all methods mentioned above have been instrumental to date, they do not 
provide structural information about the InsPs and PP-InsPs, such as the clear 
distinction of the structural isomers of PP-InsPs. The methods also lack the ability 
to monitor conversion of InsP species in real time in vitro, thereby losing 
informative kinetic insight contained within biochemical experiments. Desired 
properties of an InsP detection assay are high sensitivity for InsPs, while 
differentiating between isomers (e.g. 1PP-InsP5 and 5PP-InsP5), and not requiring 
specialized equipment. 
NMR spectroscopy can provide detailed information about the chemical and 
structural environment of a nucleus solely based on the chemical shift. For 
example, two-dimensional 1H,31P-NMR has been used to elucidate the structure of 
PP-InsPs.5,6 Since experiments utilizing the 3J(1H,31P) coupling are of limited 
sensitivity due to the inefficient magnetization transfer via these couplings, high 
analyte concentrations were necessary. In addition, the low chemical shift 
dispersion and the broad lines of 31P can limit the information content.5,6 By 
contrast, the chemical shift dispersion of the NMR-active nucleus 13C is superior to 
31P.Additionally, the sensitivity of two-dimensional experiments is much better due 
to an efficient magnetization transfer via 1J(1H,13C) one-bond couplings. 
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Consequently, 13C-labeled InsPs and PP-InsPs, should enable NMR 
measurements at low, biologically relevant analyte concentrations (Figure 3.1f). 
 
Ex vivo analysis of cellular PP-InsP pools. 
To comprehensively understand a biological pathway, it is not enough to solely 
characterize it in vitro. Proteins and enzymes might behave differently in vivo, 
making it necessary to analyze them in their endogenous settings. For InsP 
metabolism this requirement means to analyze and quantify InsP and PP-InsP 
levels inside the cell. To date, two methods are available for the analysis of cellular 
InsP pools: radioactive labeling of cell using tritiated myo-inositol, followed by 
extraction and SAX-HPLC, or alternatively, PP-InsP resolution by PAGE after 
extraction and TiO2 enrichment (Figure 3.2a). These methods are virtually identical 
to their counterparts for in vitro characterization and therefore suffer from the same 
drawbacks.  
NMR spectroscopy can take advantage of the natural abundance of 13C of only 
approx. 1 %, by isotopic labeling of selected compounds to provide targeted 
information on these labeled molecules in complex environments. Indeed, labeling 
of small molecules and metabolites with 13C has been applied widely to elucidate 
various metabolic pathways and processes.7–9 Thus, metabolic labeling of cells 
with [13C6]myo-inositol (1), should enable NMR measurements of complexed, un- 
resolved cell extracts an reveal unprecedented information about InsP metabolism 
(Figure 3.2b). 
Figure 3.2. Methods for the ex vivo analysis of inositol polyphosphates. (a) Radioactively labeled 
InsPs can be resolved via SAX-HPLC and the amount of radioactivity in each fraction is analyzed. 
(b) InsPs are enriched with TiO2-beads from complex mixtures, subsequently resolved via PAGE, 
and detected by staining with toluidine blue.   
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3.2 In vitro characterization of InsP metabolizing enzymes 
While optimizing the enzymatic synthesis of 7, we noted that the progression of 
the reaction could be followed readily by NMR spectroscopy, even in the presence 
of high concentrations of non-deuterated buffer and ATP (Figure 3.3). Specifically, 
the diagnostic signals for the protons at the 2-position of the inositol ring of 
[13C6]InsP6 and [
13C6]5PP-InsP5 were baseline-separated in the 
1H-dimension 
(5.05 ppm for 6, 4.95 ppm for 7) and showed no overlap with signals from other 
compounds within the mixture (Figure 3.3). The ability to resolve the 1H-signals at 
the 2-position provided the opportunity to monitor the enzymatic reaction in a time-
resolved fashion, using a pseudo-2D spin-echo difference experiment. This pulse 
sequence is similar to a 1H,13C-HMQC experiment and results in a series of time-
resolved one-dimensional spectra that only display resonances for 1H-nuclei that 
are bound to 13C-nuclei. By plotting the peak intensity of the 1H-nuclei at the 2-
position against time (each experiment required only 75 seconds at a substrate 
concentration of 175 µM) the progress of the kinase reaction could be observed 
(Figure 3.4). The non-invasive nature of the NMR measurements allowed for 
continuous reaction monitoring, providing time-resolved data from a single sample. 
Nevertheless, this method suffered from an unavoidable dead time of ca. 5 min at 
the beginning of each experiment due to locking, shimming, tuning and matching, 
precluding the measurement of fast reactions. 
Considering our ability to reliably measure kinase activity by NMR, we next 
wanted to determine the kinetic parameters for human IP6K1. However,  
Figure 3.3. HMQC-Spectra to determine conversion to [
13
C6]5PP-InsP5. (a) Control reaction 
without IP6KA shows no conversion of [
13
C6]InsP6. (b) Full conversion of [
13
C6]InsP6 to [
13
C6]5PP-
InsP5. (c) Overlay of a and b to illustrate that the C2 peaks are well resolved and can be used to 
monitor the reaction progress. 
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Figure 3.4. NMR-based measurements of IP6KA activity. (a) Superimposed pseudo-2D spin-echo 
difference spectra at different time points (6 min, 28 min, 50 min, 73 min, 95 min, 118 min, 455 min; 
red to purple). The InsP6 and 5PP-InsP5 peaks are labeled and the change over time is indicated 
by the arrows. The intensity of the ATP-peak hardly changed due to the ATP regenerating system. 
(b) Progress curves of [
13
C6]5PP-InsP5 synthesis at different IP6KA concentrations. An individual 
NMR-spectrum was recorded every 75 seconds. The [
13
C6]5PP-InsP5 peak height was normalized 
against the HEPES signal and the data was fitted with a first order decay model. 
 
measurement of time courses at different ATP concentrations in triplicate would 
require long allocations of NMR time. To circumvent this shortcoming, the 
reactions were quenched with EDTA after ca. 20 % conversion. In this way, the 
measurement time could be reduced to 10 min per sample instead of up to an 
hour. Furthermore, fast reactions that would exceed 20 % conversion within the 
first 5 min are amenable for characterization. 
The resulting initial rates for hIP6K1 at constant InsP6 concentration (175 µM) 
and varying ATP concentrations (62.5 µM to 8 mM) provided the Michalis-Menten 
constant (KM) for ATP and the maximum velocity (Vmax) for IP6K1 (Figure 3.5).  
The KM measured for ATP (353 ± 167 µM) was comparable to previous reports 
and is close to cellular ATP concentrations, which supports the assertion that the 
IP6Ks are uniquely sensitive to ATP availability.1,10 The Vmax value (192 ± 41 nmol 
min-1 mg-1) for IP6K1 was also within the range of published literature values, 
which varied greatly depending on the protein-tag and purification strategy (37.3 
nmol min-1 mg-1 to 1410 nmol min-1 mg-1).10,11 Interestingly, we found that ATP 
concentrations above 2 mM led to substrate inhibition of IP6K1 (Ki 7.48 mM), 
which had not been quantified before (Figure 3.5).11 The robust measurement of 
InsP conversion by NMR spectroscopy has provided kinetic data with low 
experimental error, which, in turn, has allowed the observation of substrate 
inhibition by ATP. 
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Figure 3.5. Michaelis-Menten kinetics for IP6K1. The initial velocity was measured in triplicates at 
different ATP concentrations and fitted against a model for substrate inhibition. 
 
IP6Ks regulate important aspects of metabolism and signaling in mammals and in 
pathogenic microorganisms like Trypanosoma brucei and therefore increased 
efforts to identify selective inhibitors have been made.1,12,13 Thus far, two 
molecules, TNP (N2-(m-Trifluorobenzyl)-N6-(p-nitrobenzyl)purine), and myricetin 
have been shown to inhibit IP6K1 activity at low micromolar concentrations. The 
potency of the inhibitors was characterized using radiolabeled InsPs in the case of 
TNP, and an indirect ATP-consumption assay for myricetin.1,12 Given that we could 
directly measure product formation, we expanded the scope of our NMR method 
towards the characterization of IP6K1 inhibitors. Indeed, we found that TNP and 
myricetin inhibited IP6K1 with IC50 values of 2.25 µM and 0.6 µM, respectively, 
while wortmannin, a PI3K inhibitor, did not affect enzyme activity, even at high 
concentrations (Figure 3.6). While the NMR-based method is not compatible with 
high-throughput screening to identify new kinase inhibitors, it provides a direct 
read-out of the substrate and the reaction product and is highly reliable. This type 
of assay can thus serve as a platform to develop suitable high-throughput 
screening approaches for the kinases and phosphatases involved in InsP 
metabolism and can ultimately provide the necessary validation for the discovered 
inhibitors. 
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Figure 3.6. Inhibition of IP6K1. The inhibitory effect of TNP (N2-(m-Trifluorobenzyl)-N6-(p-nitro-
benzyl)purine), Myricetin, and Wortmannin were tested at different concentrations and the IC50 
values were determined. The ATP concentration was 2.5 mM for all inhibitor‬measurements.‬(‡‬
enzyme activity at 0 µM inhibitor). 
 
Indeed, the developed NMR-based method has been used in the Fiedler group 
to develop a high-throughput assay to identify inhibitors for IP6Ks and it is now 
routinely used to characterize PP-InsP pyrophosphatases as well. 
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3.3 Characterization of A. thaliana VIH2 
Phosphate (Pi) homeostasis is an essential process in all organism (and 
especially in plants) that relies on intricate mechanisms for the sensing, uptake, 
transport and storage of Pi. Among the proteins involved in these processes, the 
SPX domain is a common motif. The small four helix bundle domain can be a part 
of larger proteins (yeast VTC2 or human XPR1) or exist as stand-alone 
proteins.14–16 It has been shown, that PP-InsPs can specifically interact with SPX 
domains and regulate their activity.16,17 Interestingly, stand-alone SPX proteins 
interact with phosphate starvation response (PHR) transcription factors in a PP-
InsP-dependent manner, establishing a link between Pi homeostasis and PP-InsP 
metabolism.16,18–21 PHR1 is a master regulator of the phosphate starvation 
response in plants. Upon binding to DNA, it upregulates transcription of P i 
starvation induced genes, enabling the plant to survive under phosphate limited 
conditions. However, PHR1 is sequestered from the DNA by binding to SPX in an 
InsP7 dependent fashion (Figure 3.7a). This connection suggests that PP-InsPs 
might be major regulators of Pi homeostasis in plants. For mammals and yeast, 
such a connection has already been established.15,16 
In order to further investigate the phosphate starvation response in plants, it is 
essential to know the biosynthetic enzymes responsible for the synthesis of PP-
InsPs. While the respective enzymes in yeast and human have been known for 
several years, identification and characterization of the plant enzymes is lacking 
behind (Figure 3.7b). VIH 1 and VIH2 have been recently identified to be the plant 
PPIP5K homologs and they were proposed to possess the same catalytic activity 
as their mammalian counterpart.22,23 So far, no enzymes with IP6K functionality 
have been described in plants (Figure 3.7b). 
Professor Hothorn approached the Fiedler group as he was interested in the 
connection between Pi starvation response and VIH1/2. They had found that 
VIH1/2 knockout plants (vih1-2 vih2-4) responded sensitively to external 
phosphate and exhibited severe growth phenotypes (Figure 3.8a,b). Furthermore, 
the Pi storage regulation seemed to be impaired as vih1-2 vih2-4 hyper-
accumulated large amounts of phosphate (Figure 3.8c). Genetic complementation 
experiments showed that a mutant of VIH2 that targeted the predicted kinase  
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Figure 3.7. The role of inositol pyrophosphates in phosphate starvation response and PP-InsP 
biosynthetic pathway in plants. (a) Schematic representation of phosphate starvation response 
regulation by PP-InsP5 (IP7). (b)Two classes of inositol pyrophosphate kinases, PPIP5K and IP6K, 
are responsible for the synthesis of inositol pyrophosphates. The schematic describes PPIP5K 
enzymes from Saccharomyces cerevisiae ScVip1, Homo sapiens HsPPIP5K11 and 2, Arabidopsis 
thaliana VIH1 and VIH2. These enzymes synthesize 1PP-InsP5 and 1,5(PP)2-InsP4 (InsP8) by 
phosphorylating InsP6 at the 1 position, and by phosphorylating 5PP-InsP5 at the 1 position, 
respectively. IP6K enzymes from Saccharomyces cerevisiae KCS1 and Homo sapiens IP6Ks 
synthesize 5PP-InsP5 and InsP8 by phosphorylating InsP6 at the 5 position, and by phosphorylating 
1PP-InsP5 at the 5 position, respectively. However, plant IP6Ks have not been reported yet. 
 
active site (VIH2KD/AA, Lys219Ala and Asp298Ala, based on homology to yeast 
vip1, Mulugu et al.24) was not able to rescue the plants. However, a mutant 
targeting the phosphatase domain (VIH2RH/AA, Arg372Ala and His373Ala, based 
on homology to yeast vip1, Mulugu et al.24) was able to rescue the growth defect 
(Figure 3.8d). Furthermore, overexpression of VIH2 and VIH2RH/AA in wildtype 
plants had only a minor effect on the Pi content, while VIH2
KD/AA led to a marked 
increase in phosphate (Figure 3.8e). All of these observations (and more, as found 
in 25) implied a strong connection between PP-InsP metabolism and the phosphate 
starvation response.  
To better understand the processes involved in the regulation, RKH 
characterized in a first step the products of VIH2 and confirmed that the kinase, 
indeed, belongs to the PPIP5K family (data not shown). I continued by 
interrogating the enzymatic activity of VIH2-phosphatase domain (PD) and VIH2-
PDRH/AA via a progress curve (Figure 3.9a). Surprisingly, both enzymes exhibited 
the same activity although the Arg to Ala, His to Ala mutation had been described 
as catalytically dead in ScVip1.24 This result was reproduced by Jinsheng Zhu in 
the Hothorn group via a malachite green assay.25 Next, ScVip1-PD and its mutant  
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Figure 3.8. vih1 vih2 loss-of-function mutants show severe growth phenotypes and hyper-
accumulate phosphate. (a) Root growth phenotypes of Col-0 wild-type and vih1-2 vih2-4 seedlings 
grown in different Pi concentrations. Plants were germinated in vertical 
1/2
MS plates for 8 d, 
transferred into Pi-deficient 
1/2
MS plates supplemented with either 0 mM, 1 mM or 10 mM Pi and 
grown for additional 12 d. Scale bars correspond to 2 cm. (b) Quantification of (a). For each boxed 
position, at least 16 independent measurements were performed for roots of seedlings from 
3 different MS plates. (c) Shoot Pi content of the wild-type (black) and vih1-2 vih2-4 (blue) 
seedlings grown under different Pi conditions as shown in (a). For each boxed position, at least 
3  ndependent measurements were performed for shoots of seedlings from 3 different MS plates. 
(d) Expression of pVIH2::VIH2
RH/AA
-mCit (Arg372Ala and His373Ala) but not pVIH2::VIH2
KD/AA
-mCit 
(Lys219Ala and Asp298Ala) rescues the vih1-2 vih2-4 mutant phenotype. Plants were transferred 
to soil 7 DAG and grown for 20 d. (e) Shoot Pi content of plants 20 DAG, over-expressing VIH2-
mCit, VIH2
KD/AA
-mCit or VIH2
RH/AA
-mCit with a Ubi10 promoter in the Col-0 wild-type background. 4 
independent plants were measured with 2 technical replicates each. The figure was taken from 
25
. 
 
ScVip1RH/AA were measured as a control and as expected, the mutant displayed 
a drastically reduced activity. It is noteworthy, that the activity level of wildtype 
VIH-PD was comparable to mutant ScVip1KH/AA but this might have been an 
artifact of the protein being shipped in dry ice as the VIH2-PD was unstable. In 
light of these results, it is not surprising that complementation of vih1-2 vih2-4 with 
VIH2-PDRH/AA mostly rescued the wildtype growth phenotype and that 
overexpression of VIH2-PDRH/AA had almost no effect on Pi content (Figure 3.8d,e). 
In animal and yeast cells PP-InsP levels are downregulated upon phosphate 
starvation, it therefore seemed natural to tested if the phosphatase activity of  
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Figure 3.9. AtVIH2
RH/AA
 is not a phosphatase dead allele. (a) The catalytic activity of VIH2 
phosphatase domain (PD) and VIH2-PD
RH/AA
 against [
13
C6]5PP-InsP5 was tested by NMR 
spectroscopy. (b) The catalytic activity of ScVip1 phosphatase domain (PD) and ScVip1-PD
RH/AA
 
against 5PP-InsP5 was tested by NMR spectroscopy. 20 mM HEPES pH* 7, 150 mM NaCl, 
1 mg/ml BSA, 175 µM [
13
C6]5PP-InsP5, 37 °C. 
 
VIH2-PD was responsive to Pi concentration.
16,26,27 However, the protein 
expression was low yielding and the enzyme unstable (personal correspondence 
with Jinsheng Zhu), so we decided to continue with the homolog ScVip1-PD and 
characterize its response to phosphate concentration as a proxy. At 10 mM Pi the 
phosphatase activity was slightly downregulated when compared to 0 mM, and 
1 mM Pi (Figure 3.10). 
After characterizing the impact of Pi concentration on the phosphatase domain’s 
activity, the question emerged how the full length (FL) enzyme would react to 
different phosphate concentrations. Such an assay proved to be logistically  
 
Figure 3.10 ScVip1-PD phosphatase activity is sensitive for phosphate concentration. The 
reactions contained 20 mM HEPES pH* 7, 150 mM NaCl, 1 mg/ml BSA, 40 µM [
13
C6]5PP-InsP5, 
and 0/1/10 mM Pi, respectively. Samples were taken at the indicated time points and the reaction 
was quenched by heating to 90 °C for 5 min. The samples were measured using a pseudo-2D 
spin-echo difference experiment and the integrals corresponding to the C2 of 5PP-InsP5 and InsP6 
were quantified. 
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Figure 3.11. Phosphate stimulates the kinase activity of ScVip1-FL. ScVip1-FL was incubated with 
40 µM [
13
C6]5PP-InsP5 in the presence of (a) 0 mM Pi, (b) 10 mM Pi, and (c) 10 mM Phi. The 
reactions were quenched after the indicated time points, measured by NMR spectroscopy, and the 
C2 peaks of InsP6, 1PP-InsP5, 5PP-InsP5, and 1,5(PP)2-InsP4 were quantified. (d) Representative 
spectrum from (a). The C2 signals are well resolved. (e) Control sample after 0 min. 
 
difficult, as the full length protein lost all kinase activity during transport from 
Geneva to Berlin. To circumvent this problem, the biochemical experiment was 
conducted in Geneva by Jinsheng Zhu and the samples were lyophilized before 
sending them to Berlin. In preparation for NMR spectroscopy measurements, the 
samples were reconstituted in D2O and all residual enzyme activity was quenched 
by a heat shock. A pseudo-2D spin-echo difference experiment was not suitable to 
analyze the samples as it would not allow for the differentiation of InsP6 and InsP8 
(the spectral resolution in the 1H dimension is not sufficient to resolve both 
signals), instead, the samples were quantified utilizing 1H,13C-HMQC spectra 
(Figure 3.11c,d). In the absence of Pi, the substrate and product concentrations of 
5PP-InsP5, and InsP6 and InsP8 remained constant over time with only little InsP8 
being made (Figure 3.11a). However, in the presence of 10 mM P i, the 
concentration of InsP8 increased in a time dependent manner to constitute the 
majority of PP-InsPs in the sample after 10 min, while 5PP-InsP5 levels decreased. 
Also after 10 min, a cross peak for 1PP-InsP5 started to appear. This data 
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solidifies the notion that PP-InsPs and VIH1/2 are involved in plant phosphate 
homeostasis. 
The NMR spectroscopy workflow developed previously could be applied to a 
question in PP-InsP metabolism. It could be shown that VIH2 is a member of the 
PPIP5K family and its catalytic activity in different conditions, plus and minus 
phosphate, was established, ascertaining the involvement of VIH1/2 in plant 
phosphate starvation response. It is noteworthy that InsP6, 5PP-InsP5, 1PP-InsP5, 
and InsP8 could be resolved and quantified in one sample, strengthening the 
advantage of NMR spectroscopy over radiolabeling or PAGE.  
The information gained in this project, highlight the easy applicability of NMR 
spectroscopy for in vitro characterization of PP-InsP metabolizing enzymes and 
promises a wide adoption of the method by the inositol pyrophosphate field in the 
future. 
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3.4 Metabolic labeling of mammalian cells with [13C6]myo-inositol 
To date, the most widely used method to assay cellular InsP and PP-InsP levels 
employs metabolic labeling of the cells with tritiated, radioactive myo-inositol. After 
incorporation into the cellular InsP and PP-InsP pools the labeled compounds are 
extracted, fractionated via SAX-HPLC chromatography, and analyzed using 
scintillation counting (Figure 3.2a). We envisioned to replace [3H]myo-inositol with 
[13C6]myo-inositol and tested the metabolic labeling of the human colon cancer cell 
line HCT116. HCT116 cells were grown in DMEM and 10 % dialyzed FBS in the 
presence of 100 µM [13C6]myo-inositol and subsequently lysed using 1 M HClO4. 
The extract was neutralized, lyophilized, dissolved in D2O, and a 
1H,13C-HMQC 
spectrum was recorded (Figure 3.12a). The spectrum displayed several strong 
peaks in the characteristic chemical shift region for InsPs and PP-InsPs (1H: 5.0 – 
3.6 ppm; 13C: 81 – 71 ppm, Figure 3.12b). At high spectral resolution a 
characteristic triplet pattern emerged due to the coupling of neighboring 13C nuclei 
in the myo-inositol ring. Comparison to an extract prepared with [12C6]myo-inositol 
Figure 3.12. Metabolic labeling of mammalian cell line HCT116, followed by NMR analysis. (a) 
General workflow for the preparation of whole cell extracts for NMR spectroscopy. (b) Left: 
1
H,
13
C 
HMQC spectrum of an HCT116 extract. The peaks from 80 to 100 ppm in the F1 and between 0 
and 3 ppm are folded into an empty region of the spectrum. Right: the inositol phosphate region of 
the spectrum is depicted in more detail. The identified InsPs are annotated while peaks that exhibit 
the expected splitting pattern in the carbon dimension but could not be attributed to either myo-
inositol (Ins), InsP5, InsP6, nor 5PP-InsP5 are highlighted by red arrows. 
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Figure 3.13. [
12
C6]myo-inositol labeled HCT116 wt cell extract. (a) The cells were grown in DMEM 
supplemented with 100 µM [
12
C6]myo-inositol and the InsPs were extracted. (b) Overlay of 
[
13
C6]myo-inositol-labeled (red) and unlabeled (black) HCT116 extracts. (c) Inositol phosphate 
region of the unlabeled HCT116 wt extract. (d) Inositol phosphate regions of overlay between 
[
13
C6]myo-inositol-labeled (red) and unlabeled (black) HCT116 wt extracts. 
 
confirmed that these peaks were a result of labeling with [13C6]myo-inositol 
(Figure 3.13). To verify that the labeling success was not limited to HCT116 cells, 
we next treated human embryonic kidney cells (HEK293T) with [13C6]myo-inositol 
and again observed robust labeling (Figure 3.14).h When cells are labeled with 
radioactive [3H]myo-inositol, their growth is slowed down. No such effect was 
observed during labeling with the benign [13C6]myo-inositol. 
To annotate characteristic resonances for endogenous InsP5, InsP6 and 5PP-
InsP5, we performed spike-in experiments with synthetic standards (see chapter 2) 
on the labeled extracts (Figure 3.15) and confirmed the presence of the above 
mentioned InsPs (as annotated in Figure 3.12). We further added a mixture 
containing synthetic InsP5, InsP6 and 5PP-InsP5 to an unlabeled extract from 
HCT116 and detected all signals at their expected chemical shifts (Figure 3.15).  
                                                             
h
 The labeling of HEK293T cells was conducted by RKH. 
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Figure 3.14. HEK293T cell extract. HEK293T cells were extracted with 1 M HClO4 and the soluble 
fraction was measured by NMR-spectroscopy. The relevant InsP peaks are labeled and additional 
peaks displaying the triplet pattern are highlighted by red arrows. 
 
For absolute quantification of InsP5, InsP6 and 5PP-InsP5, we prepared 
[13C6]myo-inositol labeled HCT116 extracts containing a known concentration of 
an internal standard (tetramethyl phosphonium bromide, PMe4Br). Resonances 
corresponding to the C2-position were integrated and referenced to a set of 
calibration curves (Figure 3.16). Assuming full replacement of the unlabeled InsP 
pools we calculated respective concentrations of 26.7 ± 2.3 µM InsP5, 29.4 ± 
7.6 µM InsP6, and 1.9 ± 0.5 µM PP-InsP5, based on packed cell volume 
(Figure 3.17a). The measured concentrations are consistent with previous 
publications with respect to InsP5 and InsP6, however, the amount of 5PP-InsP5 
determined by NMR is at least 2-fold higher.28,29 These results underline the mild 
sample preparation and the quantitative nature of NMR spectroscopy and highlight 
its potential for future measurements of labeled cells or tissues. 
The ability to quantify mixtures of InsP messengers prompted us to analyze the 
concentrations of InsP5, InsP6 and 5PP-InsP5 in HCT116 cells with perturbed PP- 
InsP metabolism. When HCT116 cells were treated for one hour with 10 mM 
sodium fluoride (NaF), an agent previously shown to elevate 5PP-InsP5 levels,
30 
the content of 5PP-InsP5 increased dramatically to an absolute concentration of 
14.7 ± 2.0 µM (Figure 3.17b). Elevated concentrations of 5PP-InsP5 were also 
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Figure 3.15. Spike in experiments to confirm the identity of InsP5, InsP6, and 5PP-InsP5 in HCT116 
extracts. (a) HCT116 extract. (b) Extract + InsP5. (10 µM final concentration) (c) Extract + InsP6. 
(10 µM final concentration) (d) Extract + 5-PP-InsP5 (5 µM final concentration). 
 
reported in cells lacking PPIP5K1 and PPIP5K2.31 We therefore grew PPIP5K-/- 
cells and indeed, a general increase of 5PP-InsP5 was detected compared to 
HCT116 wt cells (Figure 3.17c). Addition of NaF to this knock-out cell line resulted 
in extracts which contained more 5PP-InsP5 than InsP6 or InsP5 (Figure 3.17d). 
These trends of increasing 5PP-InsP5 concentrations had been observed before 
and the ratio of 5PP-InsP5 to InsP6 in all our samples was consistent with previous 
publications.31  
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Figure 3.16. Absolute quantification of InsPs from HCT116 extracts. (a) 8 µM InsP5, 10 µM InsP6, 3 
µM 5PP-InsP5 spiked into a 
12
C-labeled HCT116 extract. (b) Calibration curves for InsP C2 peak 
intensities normalized to the reference standard PMe4Br. 
 
To our surprise, the analysis of the mammalian extracts uncovered additional 
NMR signals that displayed a triplet-pattern in the carbon-dimension. These 
signals were absent in the corresponding samples prepared with unlabeled myo-
inositol and must therefore stem from metabolic labeling with [13C6]myo-inositol 
(Figure 3.12b, Figure 3.13). Interestingly, several of these signals increased upon 
NaF treatment (Figure 3.17b,d). To determine whether these signals correspond to 
other InsP or PP-InsP species, the 13C-labeled, NaF treated HCT116 wt extract 
was incubated with TiO2 beads, which enrich phosphate containing molecules.
4,32 
In addition to retaining InsP5, InsP6 and 5PP-InsP5, a putative unsymmetrical InsP 
species (InsP1 or InsP2) could be observed (Figure 3.18). Nevertheless, most 
unassigned labeled resonances were not bound by the TiO2 beads. To test for 
conversion of myo-inositol to related metabolites, spectra of D-chiro- and scyllo-
inositol – two inositol isomers that occur in human next to myo-inositol and are 
generated from it – and glucuronic acid, the canonic myo-inositol degradation 
product, were recorded (Figure 3.19a-c), none of which were superimposable with 
the unassigned labeled species.33,34  
Lastly, we considered that the additional peaks corresponded to PtdInsPs. 
However, after a phospholipid extraction, the aqueous layer still contained the  
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Figure 3.17. Changes in 5PP-InsP5 levels can be observed by NMR spectroscopy. (a) 
1
H,
13
C 
HMQC spectrum of a HCT116 wt cell extract. (b) 
1
H,
13
C HMQC spectrum of an extract of HCT116 
wt cells treated with 10 mM NaF before extraction. (c) 
1
H,
13
C HMQC spectrum of HCT116 
PPIP5K
-/-
 cell extract. (d) PPIP5K
-/-
 cells were treated with 10 mM NaF for 1h prior to extraction. 
The inserts display triplicates of absolute cellular concentration of InsP5, InsP6 and 5PP-InsP5 
based on packed cell volume. 
Figure 3.18. TiO2-enrichment of NaF treated HCT116 wt cells. Overlay of TiO2 enrichment of NaF 
treated, 
13
C-labeled HCT116 wt cell extract (red) and the original NaF treated, 
13
C-labeled HCT116 
wt cell extract (black). One set of 6 peaks (green circles) was retained that corresponds to a 
putative unsymmetrical InsP1 or InsP2 species. All other labeled unassigned peaks were removed.  
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Figure 3.19. Preliminary analysis of unannotated NMR signals. HMQC spectra of 1 mM (a) scyllo-
inositol, (b) D-chiro-inositol, and (c) glucuronic acid (highlighted with red arrows) in KClO4 saturated 
D2O. 1 mM myo-inositol was included as an internal reference (black arrows). (d) Aqueous phase 
of a lipid extraction of HCT116 wt retained all unassigned peaks except for the putative 
unsymmetrical InsP1 or InsP2 species. 
 
unidentified resonances, strongly implying a non-lipid, hydrophilic character of 
these molecules (Figure 3.19d). These observations suggest that the 
supplemented [13C6]myo-inositol has been diverted into an unknown metabolic 
pathway. Detection of these unanticipated species was only possible because the 
NMR-analysis was conducted on the crude extract and did not require a 
separation step. Elucidating the structure and function of these molecules 
connected to inositol metabolism will be of interest in the future.  
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3.5 Outlook 
The ability to use [13C6]myo-inositol to label mammalian cells and quantify the 
amount of InsPs and PP-InsPs is a powerful tool. So far, InsP5, InsP6 and PP-
InsP5 could be assigned in spectra of cell extracts. The experiments with VIH2 
showed furthermore, that it is possible to detect and quantify InsP6 and PP-InsP5, 
1PP-InsP5, and InsP8 in the same sample (Figure 3.11). This means that the 
natural abundance of these compounds in the only limiting factor for detecting 
them. The 13C-labeling is not limited to mammalian cells but quantification of InsP 
levels in other organisms is feasible, as well. In collaboration with the Hothorn 
group, labeling of A. thaliana was started and should enable the first quantification 
of PP-InsPs in plants. Another collaboration with the group of Hartmut Oschkinat 
at the FMP aims to utilize 13C- inositol for the labeleing and subsequent analysis of 
PtdInsPs with solid state NMR spectroscopy. In conclusion, the labeling of cells 
with 13C-inositol is only limited by the ability of the organism to import the 
[13C6]myo-inositol and by the intracellular concentration of the inositol derived 
compounds of interest. 
The additional peaks in HCT116 extracts that exhibit the triplet pattern, but could 
not be attributed to any InsPs, have to be identified. To this end, a mass 
spectrometry based metabolomics approach seems feasible. By comparing a 13C 
and a 12C labeled sample, the compounds responsible for the additional peaks 
should be identifiable.  
The applicability of the developed NMR-methodology to biochemical reactions 
was demonstrated with the kinetic characterization of IP6K1 and its inihitors TNP 
and myrecitin. By empoying a pseudo-2D spin-echo difference experiment, the 
measurement time for an individual sample could be reduced from several hours 
to 5 – 10 min. However, due to the low spectral resolution of such an experiment, 
this pulse program is not suited for samples containing all mammalian PP-InsPs. 
The major limitation of this method is its low sensitivity and the resulting 
requirement for higher concentrated samples. This means that, depending on 
spectral width and number of scans, compounds with a concentration of > 200 nM 
are detectable within 12 hour measurements. With a shorter measurement time of 
one hour, 1 micromolar concentrations are robustly detected. Nevertheless, for 
cells with low endogenous PP-InsPs levels or for biochemical samples that require 
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low substrate concentrations (e.g., for the measurement of the KM of IP6Ks for 
InsP6) this NMR-based method is not amenable.  
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3.6 Methods 
General Information 
All chemicals were purchased from Sigma Aldrich, VWR, Carl Roth, Thermo 
Fisher Scientific, Alfa Aesar, TCI and used without further purification unless 
stated otherwise. Deuterated solvents were purchased from Euriso-Top.  
NMR spectra were recorded on Bruker spectrometers at 600 MHz for proton 
nuclei, 151 MHz for carbon nuclei or 244 MHz for phosphorous nuclei. NMR data 
are given as follows: chemical shift δ in ppm (multiplicity, coupling constant(s) J 
Hz, relative integral) where multiplicity is defined as: s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet, br = broad or combinations of the above. 
Measurement of the metabolic extracts was performed on Bruker AV-III 
spectrometers (Bruker Biospin, Rheinstetten, Germany) at 310 K using a 
cryogenically cooled 5 mm TCI-triple resonance probe equipped with one-axis 
self-shielded gradients. The software used to control the spectrometer was topspin 
3.5 pl6. Temperature had been calibrated using d4-methanol and the formula of 
Findeisen et al.35  
For the purification via FPLC an NGC QuestTM 10 Chromatography System from 
Bio-Rad was used with an integrated NGCTM Sample Pump Module and a 
BioFracTM Fraction Collector. For the spin filtration Amicon Ultra 0.5 mL centrifugal 
filters with a cut off of 10 kDa or 3 kDa from Merck Millipore were used.  
 
Protein expression and purification 
 
Inositol hexakisphosphate kinase 1 (IP6K1) 
The codon optimized IP6K1-gene from human cloned into a pTrcHis vector (a 
kind gift from Adam Resnick) was transformed into E. coli BL21 (DE3). A 1 L 
overnight culture (37 °C) in TB supplemented with Ampicillin was diluted with 500 
mL TB, prewarmed to 37 °C. After 30 min the expression was induced with 1 mM 
IPTG. After 4 hours the cells were harvested by centrifugation (3,000 g for 10 min 
at 4 °C) and washed with ice cold water. The pellet was stored at -80 °C until 
further use. 
The frozen cells were resuspended in lysis buffer (20 mM Tris HCl pH 7.4, 150 
mM NaCl). For 1 g wet weight 10 mL lysis buffer was used. The cell suspension 
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was supplemented with lysozyme, DNase I and 1 tablet cOmpleteTM protease 
inhibitor (Roche), and incubated for 15 min on ice. The cells were lysed with a 
microfluidizer™ LM10 at 15,000 psi with five iterations. The lysate was clarified by 
centrifugation (30,000 g for 30 min at 4 °C). The supernatant was adjusted to 0.1 
% (v/v) Triton X-100, filtered (VWR® vacuum filter, PES 0.45 µm), and loaded onto 
a Co-NTA column (GE, 1 mL, HiTrap IMAC HP) that was equilibrated with lysis 
buffer with a flowrate of 1 mL/min. The column was washed with wash buffer (20 
mM Tris HCl pH 7.4, 500 mM NaCl, 50 mM imidazole, 0.1 % (v/v) Triton X-100) 
until the absorption was constant. IP6K1 was eluted with a gradient of elution 
buffer (20 mM Tris HCl pH 7.4, 500 mM NaCl, 500 mM imidazole, 0.1 % (v/v) 
Triton X-100) in wash buffer from 0-100 % over 10 CV. 1 mL fractions were 
collected. The fractions containing IP6K1 (not more than three fractions were 
used) were concentrated to 0.5 mL by spin filtration (Amicon® Ultra 0.5 mL 10K) 
and dialyzed overnight against dialysis buffer (20 mM Tris HCl pH 7.4, 500 mM 
NaCl, 1 mM DTT). The protein solution was used immediately and not frozen. 
 
NMR experiments 
 
Synthesis of inositol phosphates and inositol pyrophosphates 
[13C6]myo-inositol, [
13C6]InsP5, [
13C6]InsP6, and [
13C6]5PP-InsP5 were prepared 
according to the procedures described in chapter two. 
 
Progress curve measurement with IP6KA 
Progress curves were recorded for different IP6KA concentrations ranging from 
0.2 – 1 µM. The reactions contained 20 mM HEPES NaOD pH* 7.0, 50 mM NaCl, 
1 mM DTT, 10 mM ATP, 11 mM MgCl2, 176 µM [
13C6]InsP6Na12 (6), 5 mM creatine 
phosphate, 2 mM Me4PBr, and 1 U/mL creatine kinase in D2O. All stock solutions 
were prepared in D2O. The reactions were run in a total volume of 650 µl and 
equilibrated at 37 °C. The reactions were transferred into a 5 mm NMR tube and 
the reaction was started by the addition of the appropriate amount of IP6KA (in 
D2O buffer). The NMR tubes were inserted into the NMR instrument, locked, tuned 
and matched, and shimmed.  A spin echo difference pulse was used to measure 
consecutively 75 sec spectra until the reaction was finished. 
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Kinetic characterization of IP6K1 
The KM,ATP and Vmax were determined for IP6K1. The buffer contained 20 mM 
HEPES NaOD pH* 7.0, 50 mM NaCl, 1 mM DTT, 1 mg/mL BSA, 1 µM IP6K1, 
5 mM creatine phosphate, and 1 U/mL creatine kinase in D2O. The ATP 
concentration ranged from 8 mM to 62.5 µM (two-fold dilution series) and the 
MgCl2 concentration was adjusted to be 5 mM plus the ATP concentration. The 
reaction volume was 500 µL and the reaction was started after 10 min equilibration 
at 37 °C by the addition of 175 µM [13C6]InsP6. The reaction was quenched with 38 
µL 0.7 M EDTA (in D2O, pH* 8.0) after approximately 20 % conversion (5 min for 
IP6K1). Before the NMR measurements the pH* was adjusted to 8, if needed. The 
conversion of [13C6]InsP6 at different ATP concentration was determined by NMR 
spectroscopy. The data was fitted against a kinetic model for substrate inhibition: 
𝑣 =
𝑉𝑚𝑎𝑥
1+
𝐾𝑚
𝑆
+
𝑆
𝐾𝑖
 using SigmaPlot 12.5. 
 
Determination of IC50 values for IP6K1 inhibitors 
For the IC50 value determination a two-fold dilution series of the appropriate 
inhibitor in DMSO-d6 was used. The reactions were run in a total volume of 500 µL 
and contained 20 mM HEPES NaOD pH* 7.0, 50 mM NaCl, 1 mM DTT, 2.5 mM 
ATP, 7.5 mM MgCl2, 0.2 µM IP6K1, 1 mg/mL BSA, 5 mM creatine phosphate, and 
1 U/mL creatine kinase in D2O. The inhibitor concentration ranged from 50 µM to 
195 nM (200 x stock solutions were used). The reactions were equilibrated to 37 
°C for 10 min and initiated by the addition of 175 µM [13C6]InsP6. The reactions 
were quenched after 3 hours by the addition of 38 µL of 0.7 M EDTA (in D2O, pH* 
8.0). Before the NMR measurements the pH* was adjusted to 8, if needed. The 
conversion of [13C6]InsP6 at different inhibitor concentrations was determined by 
NMR spectroscopy. The data was fitted against a kinetic model for dose response 
inhibition: 𝑣 =
𝑏𝑜𝑡𝑡𝑜𝑚+(𝑡𝑜𝑝−𝑏𝑜𝑡𝑡𝑜𝑚)
1+
𝑥
𝐼𝐶50
𝐻𝑖𝑙𝑙𝑠𝑙𝑜𝑝𝑒  using SigmaPlot 12.5. 
 
NMR kinase assay 
Proteins encoding full-length proteins of AtVIH1 and ScVIP1, and kinase-
domains of AtVIH2 and HsVIP2 were used. 1 – 10 µM of proteins were incubated 
in a buffer containing (final concentrations) 20 mM HEPES pH 7, 50 mM NaCl, 
1mM DTT, 2.5 mM ATP, 5 mM creatine phosphate, 1 U creatine kinase, 7.5 mM 
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MgCl2 and 175 uM of [
13C6]InsP6 or [
13C6]5PP-InsP5, at a final volume of 550 µL. 
The reaction was incubated at 37°C overnight, quenched with 50 µL 0.7 M EDTA, 
lyophilized and resuspended in 600 µL of 100% D2O. Kinetic assays were 
performed similarly with the exception that the labelled InsPs were added just 
before NMR measurements and were not quenched by EDTA. 
 
Phosphatase assay 
The reactions contained 20 mM HEPES pH* 7, 150 mM NaCl, 1 mg/ml BSA, 
and 2 µM Vip1 in D2O (total volume 600 µl). Depending on the experiment, the 
reaction also contained 1 mM or 10 mM K2HPO4. The reaction was pre-incubated 
at 37 °C and started by adding 40 µM [13C6]5PP-InsP5. The reactions were 
quenched after 0, 5, 10, 20, and 40 min by boiling at 90 °C for 5 min. The samples 
were measured by NMR with a pseudo-2D spin-echo difference experiment and 
the relative intensities of the C2 peaks of InsP6 and 5PP-InsP5 were quantified. 
 
Vip1-FL assay 
Reactions were performed by Jinsheng Zhu. The reactions were lyophilized, 
dissolved in 600 µl D2O, the remaining protein was heat-inactivated for 5 min at 
90 °C and the precipitated protein removed by centrifugation. 1H,13C-HMQC 
spectra of the samples were recorded and the relative signal intensities of the C2 
peaks were quantified. 
 
Metabolic labeling of mammalian cell lines  
HCT116 wt, HCT116 PPIP5K-/- (a kind gift from Stephen Shears)31 and 
HEK293T cells were grown in DMEM lacking myo-inositol and supplemented with 
10 % dialyzed fetal bovine serum, 100 µM either [12C6]- or [
13C6]myo-inositol, and 
Penicillin/Streptomycin at 37 °C and 5 % CO2. 1 liter DMEM w/o inositol was 
prepared from pre-mixed medium components (8.1 g, Dulbecco), NaHCO3 (3.7 g), 
HEPES (10 mL of a 1 M stock, pH 7.4), l-glutamine (584 mg), l-serine (42 mg), d-
glucose (4.5 g), and NaH2PO4 (125 mg). The cells were grown in 15 cm dishes (for 
one experiment we used five to ten plates) until they reached 80-90 % confluency. 
For harvesting, cells were washed with PBS and 0.9 % NaCl solution, and 
trypsinized. The trypsin was quenched with regular DMEM. The cells were 
collected and washed two more times with PBS before lysis and extraction. The 
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packed cell volume and the cell number of the preparations were determined. If 
needed, the cells were incubated with 10 mM NaF for one hour before harvest. 
 
Inositol phosphate extraction 
All steps were performed at 4 °C. The protocol was adapted from Azevedo et 
al.36 For HCT116 wt we used ten 15 cm dishes and for HCT116 wt with NaF 
treatment, HCT116 PPIP5K-/- and HCT116 PPIP5K-/- with NaF treatment we used 
three 15 cm dishes. Cell pellets were lysed with 5 mL of 1 M HClO4, containing 3 
mM EDTA, by vortexing. The lysate was incubated on ice for 30 min before the 
precipitate was removed by centrifugation. The supernatant was neutralized with 
2 M KOH, containing 3 mM EDTA, and the pH was adjusted to 5.8-6. The resulting 
KClO4 precipitate was removed by centrifugation and the supernatant was 
lyophilized. After lyophilization the supernatant was redissolved in 1 mL D2O and 
the resulting precipitate was removed by centrifugation. The supernatant was 
lyophilized again and the residue was redissolved in 600 µL D2O containing the 
50–150 µM Me4PBr standard for absolute quantification. 
 
TiO2 enrichment 
All steps were performed at 4 °C. The protocol was adapted from Wilson et al.4 
TiO2 beads 4-5 mg were washed with 500 µL of water and 500 µL of 1 M HClO4. 
Cell extract was adjusted to pH 1 with 1 M HClO4 and added to the beads. The 
beads were rotated for 5 min and after centrifugation, the supernatant was 
discarded. The beads were washed twice with 500 µL of 1 M HClO4 and the InsPs 
were eluted by incubating the beads twice with 200 µL 2.8 % NH4OH solution. The 
eluate was lyophilized and the dry residue was dissolved in 600 µL of 1 mM MES 
(pH* 6.0) in D2O. 
 
Lipid extraction 
The lipid extraction was adopted from Clark et al.37 In summary: The cells from 3 
15 cm dishes were trypsinized and washed twice with PBS. The cells were 
resuspended in 1.7 mL Milli-Q water and 7.5 ml quench mix (48.4 mL MeOH, 24.2 
mL CHCl3, 2.4 mL 1 M HClO4) was added. The cells were lysed by vortexing for 
30 sec. 1.7 mL 1 M HClO4 and 7.25 mL CHCl3 were added to induce phase 
separation and the mixture was vortexed for 30 sec. The sample was centrifuged 
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at 3000 g for 5 min to facilitate phase separation. The top aqueous layer was 
collected and washed with 7 mL CHCl3. The aqueous layer was collected and 
neutralized with 2 M KOH containing 3 mM EDTA. The KClO4 salt was removed by 
centrifugation and the sample was lyophilized. After lyophilization the supernatant 
was redissolved in 1 mL D2O and the resulting precipitate was removed by 
centrifugation. The supernatant was lyophilized again and the residue was 
redissolved in 600 µL D2O.  
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Chapter 4: Towards mass spectrometric analysis 
of inositol poly- and pyrophosphates 
4.1 Introduction 
NMR spectroscopy provides information on the structure, chemical environment 
and concentration of a given analyte. While the information obtained is quite 
comprehensive, NMR suffers from modest sensitivity, limiting its applicability to 
analyte concentrations that often far exceed those encountered in a biological or 
cellular setting. This limitation has been partially overcome by improvements in 
instrumentation (such as the adoption of CryoProbeTM, where cryogenic cooling of 
the probe head reduces electronic noise) and methods like hyperpolarization.1 The 
most common form of hyperpolarization is dynamic nuclear polarization (DNP) 
where the spin of unpaired electrons are transferred to nearby nuclei.2 However, it 
is still not feasible to routinely detect low concentrations of InsP (in the range 
< 1 µM) samples by NMR.3  
The method of choice for dilute samples is, due to its high sensitivity, liquid 
chromatography-coupled mass spectrometry (LCMS).4 In conjunction with the 
elution time provided by the LC, MS characterizes the compounds by their mass. 
As two compounds can be isobaric (have the exact same weight, e.g. glucose and 
mannose), standards are necessary to verify the identity of the compound of 
interest. If this information is not sufficient, fragmentation can provide an additional 
layer of characterization. The most apparent limitation of MS is the lack of absolute 
quantification due to varying ionization efficiencies of different compounds. To 
overcome this limitation, an internal standard is required as a reference intensity.5  
LC-MS is an integral part in metabolomics studies:6–8 it can determine the 
relative concentrations of a given metabolite across different samples and detects 
compounds at low abundance (e.g. [dATP]cell = 0.97 µM; [FAD]cell = 5.6 µM in 
immortalized baby mouse kidney cells (iBMK)).9 Various researchers have 
successfully applied MS for the quantification of InsP6.
10–17 However, attempts 
have been limited by the physiochemical properties of InsP6, specifically the 
inherent high negative charge density. This has resulted in the reliance on anion 
exchange chromatography during the LC separation step, introducing high  
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Table 4.1. Comparison of mass spectrometry based methods for the quantification of InsP6. 
Publication Ionization mode a) LC method b) Salt concentration c) LOD d) 
Lee
15
 ESI negative WAX 110 mM (NH4)2CO3 3 pmol 
Couso
14
 ESI negative WAX 150 mM (NH4)2CO3 16 pmol 
McIntyre
16
 ESI negative SAX 70 mM KOH n.d. 
e)
 
Duong
17
 ESI negative SAX 110 mM (NH4)2CO3 25 pmol 
Rugova
13
 ICP SAX 500 mM HNO3 3 pmol 
Sjöberg
10
 ESI negative WAX 570 mM (NH4)2CO3 1 pmol 
Ito
11
 ESI negative HILIC 294 mM (NH4)2CO3 5 pmol 
Harmel
21
 NMR n.a.
 f)
 n.a. > 60 pmol 
a)
 ESI negative: electron spray ionization negative ion mode; ICP: inductively coupled plasma 
b)
 WAX: weak anion exchange; SAX: strong anion exchange; HILIC: hydrophilic interaction. 
c)
 The highest salt concentration that is injected into the ionization source during the method. 
d)
 Limit of detection of InsP6
  
e)
 not determined 
f)
 not applicable 
 
amounts of salt into the ionization source (Table 4.1). All published methods to 
date are also based on negative ion mode electron spray ionization (ESI negative). 
This ESI mode is generally considered to produce a less stable spray than its 
positive counterpart, reducing its applicability.18,19 Nevertheless, the limit of 
detection (LOD) achieved by the published methods lies in the range of 1 to 25 
pmol, exceeding the sensitivity of NMR spectroscopy 
Phosphatidylinositol phosphates also bear multiple phosphoryl groups and have 
been challenging to detect by LC-MS. Clark and coworkers developed a  
 
Figure 4.1. Derivatization of Phosphatidylinositol phosphates with TMS-CHN2 to facilitate MS 
analysis. 
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derivatization-based strategy in order to mask the negative charge and improve 
the ionization efficiency of these species. To do so, trimethylsilyl diazomethane 
(TMS-CHN2) was used to methylate phosphatidylinositol phosphates 
(Figure 4.1).20 This derivatization improved the sensitivity and allowed for the 
reproducible quantification of different PtdInsP species in cells.20 
Here, I aim to develop an InsP and PP-InsP derivatization method that facilitates 
detection and quantification of biologically relevant sub-picomole amounts of these 
compounds. This is achieved by elimination of negative charge which impedes 
efficient ionization. In addition, the derivatization would allow the separation of 
these less hydrophilic methylated compounds via a standard reverse phase 
method, reducing the burden on the mass spectrometer commonly experienced 
with the high salt concentrations required for anion exchange LC separation 
(compare Table 4.1). 
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4.2 Trimethylsilyldiazomethane methylates inositol 
hexakisphosphate 
Diazomethane (CH2N2) is a good methylating agent and has been used 
extensively for the methylation of carboxylic acids, acidic hydroxyl groups and 
thiols. The benefits of this reagent are the reaction speed (the reaction occurs 
within seconds), mild reaction conditions, the absence of non-volatile byproducts, 
and the ease of the workup.22 However, major drawbacks of CH2N2 are its 
carcinogenic nature and its propensity of explode unaccountably.23,24 
Trimethylsilyldiazomethane (TMS-CHN2) is a stabilized version of diazomethane 
(CH2N2) that must be activated before substrate methylation can occur. Activation 
proceeds via protonation of TMS-CHN2 followed by TMS deprotection by 
methanol, generating CH2N2 in situ (Figure 4.2). The diazomethane is then 
protonated by the acid, generating an electrophilic center and allowing the 
formation of the methyl ester.25,26 Desilylation is critical to ensure high yields with 
minimal side products.25 An efficient desilylation step and a protonated substrate 
are key requirements for the optimization of InsP methylation.  
A significant chemical difference between InsPs and PtdInsPs is the large 
lipophilic tail of PtdInsPs so that the derivatization can be conducted is a mixture of 
chloroform and methanol, despite the hydrophilic headgroups.20 InsPs and PP-
InsPs, however, are not soluble under these conditions. As a first step, I therefore 
screened different solvents for the methylation of InsP6 a readily available proxy of 
PP-InsPs (Figure 4.3a). Both neat MeOH and 4:1 EtOH:MeOH produced the  
 
 
Figure 4.2. Proposed mechanism for the methyl esterification of carboxylic acids. Replicated from 
Kühnel et al.
25
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highest conversion, as measured by an internal standard, and it was decided to 
continue with MeOH, as it was a less complex system to go forward. The 
activation of TMS-CHN2 requires a protonated substrate (Figure 4.2).25 Moreover, 
the protonation of InsP6 further increases the solubility of InsPs in organic solvents 
by reducing the ionic character of the compound. Therefore, the acid concentration 
was optimized and the highest yields were achieved with > 5 mM HCl (Figure 
4.3b). After the initial reaction conditions were determined, the limit of detection 
and linear detection range for the mass spectrometer had to be established. 
During testing it was found that the signal intensity of dilution series of InsP6 
plateaued below a certain concentration. However, this pattern was not detectable 
if a methylated sample was diluted after derivatization (Figure 4.4a). A possible 
explanation for this behavior is that free InsP6 undergoes aggregation under these 
solvent conditions. The aggregates could releases free, methylation-accessible 
InsP6 in a concentration dependent manner upon dilution. Due to the high 
propensity of InsP6 to form metal complexes, metal chelators (EDTA and 
[2.2.2]cryptant) were added to the methylation reaction (Figure 4.4b). Although a 
small improvement was observed, the problem remained. The addition of the 
chaotrope urea to the reaction appeared to alleviate the issue to a certain degree 
but the high concentration of urea rendered this approach impractical 
(Figure 4.4c). Saiardi and coworkers have established TiO2-enrichment as a 
practical method to enrich and purify InsPs from complex mixtures.27 Indeed, TiO2-
enrichment of the sample before derivatization eliminated the plateau trend and 
demonstrated that the linear range spans at least five orders of magnitude, 
 
Figure 4.3. Solvent screen for the methylation of InsP6 by TMS-CHN2. (a) The reactions contained 
10 mM HCl, 1 mM EDTA and [
13
C6]InsP6Me12 as an internal standard in the indicated solvents plus 
20 % MeOH. (b) The HCl concentration in the reaction was varied as indicated. 
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Figure 4.4. Non-linear response during dilution. (a) a sample containing InsP6 and 10 mM HCl in 
MeOH was diluted either before (triangle) or after (circle) derivatization. (b) The reactions 
additionally contained 1 mM EDTA and 1 mM [2.2.2]cryptant. (c) The reactions contained 
additionally 1 M urea. (d) 10 nmol InsP6 was enriched with TiO2 beads and washed either with 1 M 
perchloric acid (PA) or milli-Q water. The enriched sample was treated as in (a). 
 
providing exceptional sensitivity to levels of <10 fmol (Figure 4.4d). It appears that 
InsP6 was contaminated with some impurity that promoted aggregation, and this 
impurity was removed by the TiO2-enrichment. 
To better assess the limit of detection (LOD, signal-to-noise ratio of > 3) and the 
linear range for the detection of InsP6Me12 (11), this species was synthesized in 
order to determine the LOD independently of the derivatization efficacy. The 
synthesis of 11 involved phosphitylation-oxidation of myo-inositol with N,N-diethyl-
dimethyl phosphoamidite (S09). A stock-solution of 11 was then prepared from 
which a dilution series spanning over six orders of magnitude from 0.1 nM to 554 
µM was set up. The samples were run on a LC-MS and the lowest detectable 
concentration amounted to 8 fmol (Figure 4.5). For quantification purposes, a more 
stringent signal-to-noise ratio of > 10 is employed. This more stringent data 
analysis resulted in the same limit of quantification (LOQ) of 8 fmol. The inter-run 
variability is low (0.5 %), even at the LOQ, and it diminishes at higher 
concentrations to < 0.05 %. These results highlight the potential of the method for  
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Figure 4.5. Limit of detection for InsP6Me12. The concentration of the InsP6Me12 solution was 
determined by NMR to be 544.3 µM (against PMe4Br as internal standard). A triplicates of a dilution 
series were prepared and each sample was measured three times as technical triplicates. The data 
is shown as mean ± SD. 
 
the sensitive quantification of InsP6 and InsPs in general. The LOD of the 
synthetically prepared 11 correspondents well with the lowest detectable signal of 
derivatized InsP6 (Figure 4.4), indicating that reaction proceeds to full or close to 
full conversion. 
The association of InsP6 and InsP6Me12 with various metals during 
derivatization, chromatography, and ionization was a concern that was further 
investigated. Instead of targeted selected ion monitoring (tSIM) of the 
[InsP6Me12+H]
+ ion, a full range mass spectrum was recorded to quantify different 
potential adducts that could diminish the signal intensity. The different ion adducts 
(most prominently +Na+, +NH4
+, and +1/2 Ca2+) together accounted for only 10 % 
of the signal, making them irrelevant in terms of overall sensitivity (Figure 4.6). 
In summary, the derivatization of InsP6 was successfully established as a proof 
of principle, encouraging its application to PP-InsPs derivatization. 
 
Figure 4.6. Different ion adducts of InsP6Me12. A full-MS measurement was conducted and the 
peaks corresponding to the different ion adducts were quantified.  
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4.3 Method optimization for the methylation of InsP7 
After the establishment of standard conditions for the derivatization of InsP6, I 
re-tested these conditions for the derivatization of 5PP-InsP5. This reevaluation 
was necessary as this species contains a labile phosphoanhydride bond that may 
be incompatible with the InsP6 conditions. Indeed, upon methylation of 5PP-InsP5, 
a peak corresponding to InsP6Me12 was observed that showed higher ion counts 
than the peak corresponding to the fully per-methylated 5PP-InsP5Me13 (12). This 
observation indicated that degradation of 5PP-InsP5 was occurring under these 
reaction conditions. Variations in reaction time, HCl concentration, solvent, and 
acid composition did not lead to improvement (Figure 4.7). In order to develop 
strategies to reduce the degradation, an understanding of the mechanism is 
required. There are three stages of the workflow during which the degradation 
could occur: the methylation reaction itself, the acid quench of the remaining 
diazomethane, and liquid chromatography preceding the MS analysis. During LC, 
the acidic, aqueous conditions could lead to hydrolysis of the phosphoanhydride 
bond, generating InsP6Me11 (13) and (MeO)2OPOH (Figure 4.8 green and red 
arrow). Shortening of the LC gradient led to no change in ion counts, indicating 
that the LC was not the source of the degradation. During methylation and acidic 
quench, both hydrolysis and methanolysis could occur. However, quenched 
samples were stable over several days, suggesting that the methylation reaction 
itself was problematic.  
 
Figure 4.7. 5PP-InsP5 methylation conditions. 1 µM 5PP-InsP5 was methylated under the indicated 
conditions in MeOH (the reaction was quenched after the indicated time points) and the ion counts 
of the derivatization products are displayed. 
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Figure 4.8. Potential mechanisms of hydrolysis of 5PP-InsP5 during methylation with TMS-CHN2. 
 
Table 4.2. Quantification of 5PP-InsP5 methanolysis products. 
Solvent (MeO)2OPO
H 
(MeO)3OP(d3
) 
(MeO)3O
P 
InsP6Me12(d3
) 
InsP6Me12 InsP7Me13 
MeOH-
d3 
0.86 0.02 0.13 0.14 0.33 0.19 
MeOH 0.81 0.00 0.19 0.00 0.45 0.33 
 
In order to quantify the contribution of methanolysis and hydrolysis to the 
degradation of 7, I performed the reaction in MeOH-d3 and regular MeOH, making 
it possible to track potential methanolysis products by a mass shift of +3 m/z and 
distinguish these products from a TMS-CHN2 methyl group (Figure 4.8 blue and 
black arrows, Table 4.2). Based on the relative signal intensities, a third of 11 is 
the product of methanolysis, while the other two thirds are due to hydrolysis of 7 
followed by methylation.  
To stabilize the phosphoanhydride bond, I hypothesized that increasing the 
electron density at the phosphorus would reduce its electrophilicity and therefore 
increase its stability towards hydrolysis or methanolysis. To this end, diazo ethane 
(14) and diazo propane (15) were synthesized and subsequently applied in 
alkylation reactions of 5PP-InsP5 (Figure 4.9). However, the extent of degradation 
remained constant in both cases.  
An alternative approach was to exploit the methanolysis reaction by using 
MeOH-d3 as a solvent thus introducing a mass shift in 5PP-InsP5 derived 
InsP6Me12. For this approach to be useful, the proportion of methanolysis had to 
be increased and the hydrolysis decreased. Different acids were screened for their 
ability to promote methanolysis (Figure 4.10). Reactions performed in the 
presence of toluenesulfonic acid and perchloric acid displayed the highest amount 
of InsP6Me12, but generated significant amounts of InsP5Me10 and InsP6Me11 as 
well, thereby invalidating this approach of forced methanolysis. 
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Figure 4.9. Diazoethane and diazopropane do not reduce hydrolysis of 5PP-InsP5. (a) (i) HCl, 
urea, NaNO2, H2SO4, H2O, 5 h, 0 °C → reflux → 0 °C. (ii) 40 % (w/v) KOH (aq), Et2O, 30 min, 0 °C. 
(b) The alkylation was performed with 10 mM HCl in MeOH. 
 
In a complementary strategy, I tried to stabilize the phosphoanhydride bond by 
buffering the reaction. Use of Bis-(2-hydroxyethyl)-amino-tris(hydroxymethyl)-
methane (BisTris) showed promising results and yielded for the first time 5PP-
InsP5Me13 levels that were higher than InsP6Me12 (Figure 4.11). This result was 
surprising as the methylation mechanism by TMS-CHN2 requires a protonated 
substrate, which should not be the case in the presence of BisTris. It remains 
unclear why this condition worked so well. 
During the course of the experiments, I noticed varying results based on the 
production-lot of TMS-CHN2 (purchased as a 2 M solution in diethyl ether from 
Sigma Aldrich). To systematically test the influence of the reagent on the quality of 
the methylation reaction, different TMS-CHN2 solutions (in various solvents and 
 
Figure 4.10. Maximizing 5PP-InsP5 methanolysis. 1 µM 5PP-InsP5 was methylated with TMS-
CHN2 under the indicated conditions in MeOH and the ion counts of the derivatization products are 
displayed. 
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Figure 4.11. Methylation of 5PP-InsP5 under buffered conditions. 2 µM 5PP-InsP5 was methylated 
with TMS-CHN2 in the presence of 10 mM of the indicated buffers. 
 
from distinct commercial sources) were tested (Figure 4.12). The proportion of 13 
remained constant across all reagents but the achievable signal intensity varied 
greatly, with the TMS-CHN2 in diethyl ether from Sigma Aldrich giving the best 
result. The large variability of the results indicated to us that contaminants in the 
reagent might be responsible for the low yielding methylation reactions. The same 
impurities might play a role in promoting the hydrolysis of 7, as well. 
To test this hypothesis, I prepared diazomethane (16) as a solution in diethyl 
ether from N-Methyl-N-nitroso-p-toluenesulfonamide (S11) and purified it by 
distillation (Figure 4.13a). Compared to TMS-CHN2, methylation of a HCT116 cell 
extract with 16 displayed a higher overall signal intensity. Furthermore, the 
standard deviation for the triplicates was constantly smaller for the diazomethane 
samples (Figure 4.13b), indicating the reaction was more consistent. This result 
highlights the potential of clean 16 for the derivatization of PP-InsPs. 
 
Figure 4.12. Differing quality of TMS-CHN2 sources. TMS-CHN2 from different vendors (Sigma 
Aldrich, TCI, Alfa Aesar, Acros Organics) in different solvents was tested. 1 µM 5PP-InsP5 was 
methylated in 10 mM HCl in MeOH. 
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Figure 4.13. Diazomethane methylates inositol pyrophosphates. (a) Synthesis of diazomethane (i) 
NaNO2, AcOH, H2O, 20 min, 0 °C. (ii) KOH, EtOH, Et2O, 20 min, 65 °C. (b) The TiO2 enriched cell 
extract of [
13
C6]myo-inositol labeled yeast (25 ODs) was methylated using TMS-CHN2 or CH2N2 in 
MeOH with either 10 mM BisTris or 10 mM HCl. The samples were measured as technical 
triplicates. 
 
Another explanation for the relatively high signal intensity of 5PP-InsP5 
degradation products in the MS measurements could be a difference in ionization 
efficiency between the compounds. Therefore, equal amounts of non-hydrolysable 
PP-InsP bisphosphonate-analogs (5PCP-InsP5, and 1,5(PCP)2-InsP4, a kind gift 
from Sarah Hostachy and Katy Franke) were derivatized, their detectable ion 
count quantified, and compared it to InsP6Me12 (Figure 4.14). Surprisingly, the 
ionization efficiency dropped drastically to 27.9 % and 8.7 %, respectively, adding 
another level of difficulty in addition to the degradation of PP-InsPs during the 
methylation. 
 
Figure 4.14. Ionization efficiency differs for PP-InsPs. (a) Structures of 5PCP-InsP5 and 1,5(PCP)2-
InsP4. (b) 1 µM InsP6, 5PCP-InsP5, and 1,5(PCP)2-InsP4 were methylated with TMS-CHN2 and the 
ion count is displayed.  
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4.4 Application of the derivatization strategy to biological 
samples 
Although the initial results for the methylation of InsP6 and 5PP-InsP5 did not 
lead yet to a usable method, they were promising enough motivate me to measure 
InsP levels in biological samples. As a first approach, several S. cerevisiae strains 
with genetic knock outs of InsP-metabolizing genes were tested (genes listed in 
Figure 1.1 and Table 4.3). Overnight cultures were extracted using perchloric acid 
and the PP-InsPs were enriched over TiO2 beads. The samples were methylated 
with TMS-CHN2 and the derivatized samples measured by LCMS.  
To our delight, the results mirrored the literature description of the respective 
knock out strains: Yeast lacking IPK1 (ipk1Δ) and unable to generate InsP6, 
showed an increase in the precursor InsP5 and a marked decrease in InsP6.
28 A 
KCS1 (the yeast IP6K homolog) knockout strain (kcs1Δ) retained wildtype-like 
levels of InsP5 and InsP6 while displaying reduced levels of InsP7.
29 Finally, strains 
with knockouts of VIP1 (vip1Δ), and SIW14 (vip1Δsiw14Δ) accumulate 5PP-InsP5 
due to their inability to further metabolize this compound and, indeed, the strains 
exhibited increased InsP7 levels compared to wildtype (Figure 4.15a).
30 While the 
detectable changes were not as drastic as described in the literature, these results 
nevertheless highlight the potential of a derivatization based LC-MS method to 
analyze InsP and PP-InsP levels in cellular samples.28–30 To show the applicability 
of this method in profiling the InsP content of more complex organisms, whole C. 
elegans and mammalian HEK293T cells were subjected to the same workflow and 
the samples measured (Figure 4.15b). InsP5, InsP6 and InsP7 could be detected 
and to our knowledge this is the first demonstration that C. elegans contains PP-
InsPs. 
 
Table 4.3. Effect of genetic knockouts on cellular PP-InsP levels 
Genotype Effect on 
Yeast Human InsP6 InsP7 
a)
 InsP8 
ipk1Δ IPK1 n.d. 
b)
 n.d. n.d. 
kcs1Δ IP6K Unchanged n.d. 
c)
 n.d. 
vip1Δ PPIP5K Unchanged Increased n.d. 
siw14Δ vip1Δ  Unchanged Increased n.d. 
a)
 combined levels of 1PP-InsP5 and 5PP-InsP5. 
b)
 not detectable. 
c)
 small amounts of 1PP-InsP5 remain that are usually not detectable. 
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Figure 4.15. Methylation of various cellular extracts. (a) 25 ODs of cells were taken from overnight 
cultures. The InsPs were extracted and enriched over TiO2. The enriched samples were 
methylated with TMS-CHN2 and measured on a Q-Exactive. (b) C. elegans wt worms (50 µl) were 
lysed with glass beads in 1 M perchloric acid and the extract was treated as in a. HEK293T cells 
were trypsinized (PCV: 25 µl) and lysed in 1 M perchloric acid and the extract was treated as in (a). 
 
Although yeast contains similar amounts of InsP7 and InsP8, no InsP8 could be 
detected in any of the cellular samples. In light of the InsP7 degradation during 
methylation and the differences in ionization efficacy, this is not surprising, as the 
InsP7 signals were already only barely above the background (see Chapter 4.3). 
To establish whether cellular InsP8 was detectable, I methylated a PP-InsP extract 
from D. discoideum, a slime mold with the highest reported PP-InsP concentration 
in an organism (up to 180 µM).31 In this extract, both InsP7 and InsP8 were 
observed, confirming that InsP8 is technically detectable provided the 
concentration is high enough (Figure 4.16). 
After these proof of principle experiments, I measured the incorporation kinetics 
of [13C6]myo-inositol in growing yeast. This knowledge is important in the context  
 
 
Figure 4.16. Detection of InsP8 in D. discoideum. The indicated volume of an extract from D. 
discoideum (a kind gift from Adolfo Saiardi) was methylated with TMS-CHN2 and analyzed by LC-
MS. 
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Figure 4.17. [
13
C6]myo-inositol incorporation in yeast. (a) Yeast was inoculated into SD medium 
supplemented with 475 µM [
13
C6]myo-inositol at OD 0.1 and grown at 30 °C. Every hour the optical 
density was measured and 5 ODs of cells were collected. The cells were lysed with bead beating in 
1 M perchloric acid and the extract was enriched over TiO2 beads. The samples were methylated 
with TMS-CHN2 and measured on a Q-Exactive. (b) Yeast was inoculated at OD 0.1 into SD 
medium supplemented with varying concentrations of [
13
C6]myo-inositol and grown overnight. The 
samples were prepared as in (a). 
 
of metabolic labeling of cells with [13C6]myo-inositol for NMR measurements (see 
Chapter three). By directly monitoring the incorporation into InsP6 via LC-MS, we 
would be able to optimize labeling time and [13C6]myo-inositol concentration. For 
this experiment, wildtype yeast was grown in SD medium, supplemented with 
475 µM [13C6]myo-inositol, and samples taken every hour. The rate of [
13C6]InsP5 
and [13C6]InsP6 increase was the same as the rate of [
12C6]InsP5 and [
12C6]InsP6 
decrease and matched the growth rate of yeast, indicating that under these 
conditions yeast does not synthesize myo-inositol de novo (Figure 4.17a). In order 
to establish the required amount of [13C6]myo-inositol in the medium to prevent the 
de novo synthesis, different concentrations were tested (100 µM - 1000 µM). Even 
at 100 µM [13C6]myo-inositol de novo synthesis was not observed (Figure 4.17b). 
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4.5 Outlook 
The presented work highlights the potential of a derivatization-based MS 
approach to measure and quantify InsPs and PP-InsPs at biologically relevant 
concentrations. The derivatization reaction appears to be high yielding and the 
mass spectrometry sensitivity is outstanding, especially when compared to 
existing methods (compare Table 4.1). It is promising that biological samples can 
be analyzed with this approach.  
The envisioned method worked well for InsP6 with minimal methodology 
refinement. With further optimization, this method holds great potential for the 
analysis of InsP6 and lower inositol phosphates. Access to 
13C-labeled InsP5 and 
InsP6 would allow the incorporation of these compounds as internal standards in 
order to measure endogenous InsPs quantitatively.  
The method is in principle also suitable for the analysis of metabolic fluxes. 
Currently, it is poorly understood how the interconversion of InsPs proceeds and 
the mechanisms by which these processes are regulated. The highly sensitive 
detection of small amounts of analytes enables the pursuit of pulse-chase-type 
experiments with 13C-labeled myo-inositol or 18O-labeled phosphate to dissect the 
underlying regulatory mechanisms. The introduction of an internal standard will 
facilitate the quantitation of endogenous levels of InsPs in different tissues and 
under various conditions to test the standing paradigms that the InsP pool is rather 
static. The high sensitivity and the resulting low requirement for sample amounts 
will allow for the quantification of InsPs and PP-InsPs in various organelles. 
Especially PP-InsP levels in the nucleus will be informative as GO-term analyses 
of PP-InsP interacting proteins contained nuclear processes (e.g., nucleolus and 
RNA pol I/III complex).32 Efforts towards these aims are ongoing. 
While the method optimization for the InsPs appears to be straight-forward, this 
cannot be said about the PP-InsPs. Detection of these compounds suffers two 
major drawbacks. On the one hand, the compounds are partially degraded during 
the methylation, while on the other hand, the ionization efficiency drops drastically 
with increasing numbers of pyrophosphate groups. Both processes especially 
hamper the detection of InsP8. At the moment, the avenue to an effective 
derivatization and detection method remains questionable. Forcing the hydrolysis 
of the phosphoanhydride bond in order to label the PP-InsPs with Me-d3 groups is 
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not promising as there appear to be several competing degradation pathway. A 
more promising approach might be the use of generator-produced and distilled 
diazomethane, as this gave the highest levels of 5PP-InsP5Me13 during the 
screening of conditions. Further reaction optimization might prove this avenue 
viable.  
If the PP-InsP degradation cannot be avoided after all, another possible strategy 
could be to quantify the amount of degradation in each sample based on an 
internal 13C-labeled standard in order to back-calculate the original PP-InsP 
concentrations in the sample.  
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4.6 Methods 
General Information 
All chemicals were purchased from Sigma Aldrich, VWR, Carl Roth, Thermo 
Fisher Scientific, Alfa Aesar, TCI and used without further purification unless 
stated otherwise. Deuterated solvents were purchased from Euriso-Top. Telos® 
was ordered from Kinesis. Normal phase flash chromatography was performed 
using analytical grade solvents and silica gel from VWR (40-63 µm) as stationary 
phase. Automated flash chromatography was performed using gradient grade 
solvents on a CombiFlash® Rf from Teledyne Isco using prepacked CombiFlash® 
columns (40-63 µm). LC-MS analysis was carried out with an Agilent 1260 Infinity 
Binary LC system connected to an Agilent 6130 Quadrupole LC/MS system with a 
ZORBAX Rapid Resolution HT Narrow Bore SB-C18 1.8 μm column (2.1 x 50mm) 
at 30 °C using API-ESI (atmospheric pressure ionization-electrospray) in positive 
ion mode. The eluent consisted of 10% ACN in water with 0.1% formic acid at 0.7 
mL/min flow rate.  
NMR spectra were recorded on Bruker spectrometers operating at 300 or 600 
MHz for proton nuclei, 75 or 151 MHz for carbon nuclei or 122 and 244 MHz for 
phosphorous nuclei. NMR data are given as follows: chemical shift δ in ppm 
(multiplicity, coupling constant(s) J Hz, relative integral) where multiplicity is 
defined as: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad 
or combinations of the above. The software used to control the spectrometer was 
topspin 3.5 pl6. Temperature had been calibrated using d4-methanol and the 
formula of Findeisen et al.33  
High-resolution mass spectrometer was performed by direct inject on an 
OrbitrapTM Q-Exactive mass spectrometer (Thermo Fisher Scientific). The 
derivatized samples were analyzed with an Unltimate 3000 UHPLC system 
connected to an OrbitrapTM Q-Exactive with a Agilent poroshell EC-C18 2.7 µm 
column (4.6 x 150 mm) in positive ion mode at a resolution of 70,000. The eluent 
consisted of ACN in water with 0.1 % formic acid at 0.15 ml/min flow rate. 
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Synthesis 
 
 
Dimethyl N,N-Diethylphosphoramidite (S09) 
Dimethyl N,N-Diethylphosphoramidite was synthesized according to a procedure 
from Johns and colleagues.34 
 
 
Dodecamethyl inositolhexakisphopshate, InsP6Me12 (11) 
The compound was synthesized based on a method by Podeschwa and 
coworkers.35 S09 (962 mg, 5,83 mmol) was added to a suspension of myo-inositol 
(150 mg, 0,83 mmol) and 1H-tetrazole (700 mg, 9,99 mmol) in anhydrous 
Dichloromethane (60 ml) and the solution was stirred overnight at room 
temperature. For work up the solution was cooled to -40 °C and an anhydrous 
solution of mCPBA (4307 mg, 17,19 mmol) in DCM (45 ml, dried with Na2SO4) 
was added. The solution was allowed to warm to room temperature, and the 
stirring was continued for another hour. The reaction mixture was diluted with 
DCM (150 ml) and washed consecutively with aqueous Sodium bisulfite (20 %, 
100 ml, twice) and saturated NaHCO3 (three times, 100 ml). After evaporation the 
product was purified via flash chromatography with a gradient of 0 to 50 % MeOH 
in DCM. The yield was 10 %. 
1H NMR (600 MHz, D2O) δ 3.92 (m, 36H), 4.67 (q, J = 8.8 Hz, 1H), 5.26 (d, J = 
8.8 Hz, 1H). 
13C NMR (151 MHz, D2O) δ 55.5 (b), 72.7, 74.98, 75.18, 75.42 
31P NMR (243 MHz, D2O) δ -3.85, -2.73, -2.28, -2.09. 
HRMS (ESI/Orbitrap) m/z: [M + H]+ calcd. for C18H43O24P6 829.0564; Found 
829.0554. 
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N-nitroso-N-ethyl urea (S10) 
N-nitroso-N-ethyl urea (S10) was synthesized according to a procedure from 
Dyer and colleagues.36 A solution of ethyl amine (6000 mg, 93.17 mmol) in water 
(14.1 ml) was cooled in an ice bath and neutralized by the addition of saturated 
HCl (8.7 ml). Urea (18.633 g, 310.25 mmol) was added and the solution was 
refluxed for 3 h. Sodium nitrite (6.85 g, 99.32 mmol) was added and the solution 
was cooled in a dry ice-acetone bath and during 1 h siphoned under the surface of 
a stirred mixture of sulfuric acid (6.2 g, 63.3 mmol) and ice (40 g) which was also 
cooled by a dry ice-acetone bath. The frothy precipitate was collected by filtration 
and washed 3 times with ice cold water. 
 
 
Diazoethane (14) 
Diazoethane (14) was synthesized according to a procedure from Dyer and 
colleagues.36 N-nitroso-N-ethyl urea (S9) (131.14 mg, 1 mmol) was added to a 
mixture of Et2O (1.4ml) and 40 % (w/v) KOH (aq) (0.4 ml) at 0 °C. The mixture was 
allowed to stand for 30 min at 0 °C. The ethereal solution was removed with a 
glass pipette and directly used. 
Due to the volatile nature, no NMR or HRMS was taken. 
 
 
N-nitroso-N-propyl urea (S11) 
N-nitroso-N-propyl urea (S11) was synthesized according to a procedure from 
Dyer and colleagues.36 A solution of n-propyl amine (5000 mg, 84.59 mmol) in 
water (14.1 ml) was cooled in an ice bath and neutralized by the addition of 
saturated HCl (8.7 ml). Urea (16.917 g, 281.68 mmol) was added and the solution 
was refluxed for 3 h. Sodium nitrite (6.22 g, 90.17 mmol) was added and the the 
solution was cooled in a dry ice-acetone bath and during 1 h siphoned under the 
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surface of a stirred mixture of sulfuric acid (5.6 g, 57.1 mmol) and ice (34 g) which 
was also cooled by a dry ice-acetone bath. The frothy precipitate was collected by 
filtration and washed 3 times with ice cold water. 
 
 
Diazopropane (15) 
Diazopropane (15) was synthesized according to a procedure from Dyer and 
colleagues.36 N-nitroso-N-propyl urea (S10) (131.14 mg, 1 mmol) was added to a 
mixture of Et2O (1.4ml) and 40 % (w/v) KOH (aq) (0.4 ml) at 0 °C. The mixture 
was allowed to stand for 30 min at 0 °C. The ethereal solution was removed with a 
glass pipette and directly used. 
Due to the volatile nature, no NMR or HRMS was taken. 
 
 
N-Methyl-N-nitroso-p-toluenesulfonamide, Diazald (S12) 
N-Methyl-N-nitroso-p-toluenesulfonamide (S11) was synthesized according to a 
procedure from Ouwerkerk and colleagues.37 N-Methyl-p-toluenesulfonamide 
(9.26 g, 50 mmol) was dissolved in acetic acid (80 ml) and the solution was cooled 
on ice. NaNO2 (5.17 g, 75 mmol) was dissolved in water and over the course of 20 
min dropped into the reaction. The reaction solution was stirred for 20 min and 
subsequently diluted with water (200 ml). This solution was extracted three times 
with ether. The organic layers were combined, washed with saturated bicarbonate 
and dried over Na2SO4. The ether was evaporated to afford the title compound in 
96 % yield. 
1H NMR (600 MHz, CDCl3) δ 7.89 (d, J = 9 Hz, 2H), 7. 4 (d, J = 8 Hz, 2H), 3.15 (s, 
1H), 2.48 (s, 1H). 
13C NMR (151 MHz, CDCl3) δ 146.13, 134.11, 130.36, 128.01, 28.9, 21.75 
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Diazomethane (16) 
     Diazomethane was synthesized in a Diazald reactor from Sigma-Aldrich 
according to the manufacturer’s instructions. Fill the condenser with dry ice, then 
add isopropanol slowly until the cold-finger is about one-third full. Add ethanol 
(95%, 6 mL) to a solution of potassium hydroxide (3 g) in water (4,8 mL) in the 
reaction vessel. Attach a 100 mL receiving flask (with Clear-Seal joint) to the 
condenser and cool the receiver in dry ice/isopropanol bath. Provide an ether trap 
at the side-arm (the glass tube must have firepolished ends). The trap should be 
cooled in a dry ice/isopropanol bath. Place a separatory funnel (with Clear-Seal 
joint) over the reaction vessel and charge the funnel with a solution of N-Methyl-N-
nitroso-p-toluenesulfonamide (S12) (3,0 g, 14 mmol) in ether (27 mL). Warm the 
reaction vessel to 65 °C with a water bath and add the Diazald solution over a 
period of 20 minutes. The rate of distillation should be approximately the rate of 
addition. Replenish the cold-finger with dry ice as necessary. When all the Diazald 
has been used up, slowly add 10 mL of ether and continue the distillation until the 
distillate is colorless. If the distillate is still yellow, add another 10 mL of ether and 
continue the distillation.  
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